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Abstract: Background: We evaluated efficacy, pharmacokinetics (PK), and safety of clofazimine
(CFZ) in HIV-infected patients with cryptosporidiosis.
 
Methods: We performed a randomized, double-blind, placebo-controlled study. Primary
outcomes in Part A were reduction in  Cryptosporidium  shedding, safety, and PK.
Primary analysis was according to protocol (ATP). Part B of the study compared CFZ
PK in matched HIV-infected individuals without cryptosporidiosis.
 
Results: Twenty Part A and 10 Part B participants completed the study ATP. Almost all
Part A participants had high viral loads and low CD4 counts, consistent with failure of
antiretroviral (ARV) therapy. At study entry, the Part A CFZ group had higher
Cryptosporidium  shedding, total stool weight, and more diarrheal episodes compared
to the placebo group. Over the inpatient period, compared to those who received
placebo, the CFZ group  Cryptosporidium  shedding increased by 2.17 log  2
Cryptosporidium  per gram stool (95% upper confidence limit: 3.82), total stool weight
decreased by 45.3 g (p=0.37), and number of diarrheal episodes increased by 2.32
(p=0.87). The most frequent solicited adverse effects were diarrhea, abdominal pain,
and malaise. Three CFZ and 1 placebo subjects died during the study. Plasma levels
of CFZ in participants with cryptosporidiosis were 2-fold lower than Part B controls.
 
Conclusion: Our findings do not support the efficacy of CFZ for the treatment of
cryptosporidiosis in a severely immunocompromised HIV population. However, this trial
demonstrates a pathway to assess the therapeutic potential of drugs for
cryptosporidiosis treatment. Screening persons with HIV for diarrhea, and especially
Cryptosporidium  infection, may identify those failing ARV therapy.
Response to Reviewers: William A. Petri, MD
Associate Editor, Clinical Infectious Diseases
9 March 2020
Dear Dr. Petri,
Thank you for considering our original study titled: “Clofazimine for treatment of
cryptosporidiosis in HIV-infected adults (CRYPTOFAZ): an experimental medicine,
randomised, double-blind, placebo-controlled phase 2a trial” for publication in Clinical
Infectious Diseases. We also thank the reviewers for their thoughtful comments, and
believe the revised manuscript has been improved as a result. Below we have listed
our response to reviewer comments:
Reviewer #1: Drugs to treat Cryptosporidiosis in severely immunocompromised
patients, particularly those with HIV/AIDS, are not available and are urgently needed.
This study was an attempt to see whether an existing drug, Clofazamine (CFZ), which
has given very promising results in animal models, would be effective in this
population.
There are clearly issues with this trial. Recruitment proved unexpectedly difficult, which
resulted in smaller treatment and control groups than the authors wanted, although
they reached  the sample size (10 in each group) that they calculated would have
sufficient power to give an 80% chance of detecting a significant difference between
the groups. And, despite randomisation, the two groups turned out to be very different
in many important parameters.
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I have one small change that I would like to see in the manuscript. On page 4 of the
Supplementary appendix (1.6) we are told that calf data suggested that 10 persons in
each arm would give adequate power to this trial. We are not given a reference to the
calf data; I think we should see that and the numerical data that went into the power
calculation.
Author response: The calf data showing partial, limited efficacy of CFZ is in the process
of being written up.  Therefore, in the Supplementary Appendix we have clarified this
as ‘unpublished data, Michael Riggs, University of Arizona’ (Supplementary Appendix,
p4).
The lack of benefit from CFZ will be disappointing to many and the problems with this
trial suggest that it won't be the last word on the subject, but the apparent dis-benefit of
the drug on parasite excretion in the treatment group (although non-significant) will
increase confidence in the author's conclusions.
Author response: Thank you, we agree.
Reviewer #2: This is a well-written manuscript reflecting a carefully performed study in
an extremely ill patient population comparing clofazamine to placebo in HIV-associated
cryptosporidial diarrheal disease. Unfortunately, by chance apparently, the
randomization did not produce groups that were comparable in a number of important
metrics- most notably CD4 count, symptom severity and number of co-pathogens that
could cause diarrhea. The authors present data that attempt to make a conclusive
case that clofazimine was not efficacious - for example the trajectories of diarrhea
severity, stool weight and consistency as well as organism burden over time. These
are fairly convincing that clofazamine had no efficacy but because the clofazamine arm
was sicker at baseline it is difficult to be completely convinced that this study is
conclusive.
The authors could possibly bolster the argument that there was no efficacy of
clofazamine despite the poorer baseline status of the clofazamine arm. For example,
were the stool co-pathogens treated and if so, was there followup testing to document
clearance of these pathogens or any time between the treatment of co-pathogens and
the beginning of the study? It would be reassuring that the poor outcomes in the CFZ
group were not attributable to these infections rather than lack of efficacy of
clofazamine.
Author response: Subjects hospitalized with symptomatic diarrhea were managed by
the clinical team and treated with ciprofloxacin, which is the standard of care. The stool
TaqMan assay results were not performed in real-time and therefore results were not
available until after conclusion of the study. We clarified this in the discussion (p15).
Also it should be noted that the primary outcome was a change in cryptosporidium
excretion, and not change in diarrhea.  We have clarified this in the discussion also
(p15).
I think it is important to detail the inclusion criteria in the primary manuscript rather than
the supplementary materials- for example, the reader should be aware that part A
participants were already on antiretroviral therapy and only needed to have diarrhea for
3 days to qualify. Also that part B participants were matched by age, gender and
weight but not HIV disease stage.
Author response: We have included eligibility criteria in the primary manuscript (p5).
The Part B matching information is listed on p6 L126.
For clarity:
Line 209- please clarify if these differences between the groups were statistically
significant.
Author response: Since we used a randomized study design, which is the gold
standard to ensure equal distribution between groups, we did not conduct statistical
analysis to compare differences. In addition, the group sizes are really too small to infer
statistical significance. We expect that if the trial had continued to recruit subjects, the
resulting groups would be large enough that such differences as what we observed
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would be negligible.
The fatalities- it would be helpful to briefly describe these in the main manuscript- it
appears that none were felt by the DSMB to be related to the study drug but rather due
to the severe underlying illnesses these patients all had. Describing them as "AEs with
fatal outcome" implies they were from the trial- that may be required language that I'm
unaware of.
Author response: We have briefly summarized these fatalities in the main manuscript
(p11).
The Tables should have some indication of which of the characteristics were
significantly different between the groups- in footnotes or bolded values for example.
Author response: Since we used a randomized study design, which is the gold
standard to ensure equal distribution between study groups, we did not conduct
statistical analysis to compare differences. Furthermore, the group sizes are really too
small to infer statistical significance. Therefore, we presented the data as collected.
Figures: Would spell out Change from Baseline
Author response: Due to Figure size limitations we did not spell out Change from
Baseline on the actual figure, but the abbreviation is spelt out in the figure legend (p18-
19).
Line 300: I'm not sure I understand this paragraph- why would you screen for diarrhea
to predict people at risk for TB and ARV failure?
Author response: Malawi is a resource-limited setting where HIV viral loads and CD4
counts are not routinely done. Therefore, care is usually provided based on clinical
presentation. Based on our findings in the study population, we suggest using
presence of diarrhea as a screening proxy for HIV-infected immunosuppressed
individuals at higher risk for TB and ARV failure. We have clarified this in the
Supplementary Appendix (Supplementary p3).
Line 316: This is the first we learn that the authors believe that Cryptosporidium was
not driving diarrhea in up to 7 of the participants- which group did these participants fall
into? How does that effect their assertion that CFZ was not efficacious? Line 320 and
321-do the authors believe that cryptosporidium was not responsible for the diarrhea in
those who did not meet the cutoffs?
Author response: On L216-217 we stated that the CFZ group has “more pathogens
detected at higher quantities (67% v. 30%), and clarified in the same paragraph (L330-
334) the issue of GEMS diarrheagenic amounts. We have re-organized the paragraph
so that the information is clearer (p10).  However, please note the primary efficacy
outcome was reduction in cryptosporidium shedding and not diarrhea resolution.  We
knew that it was likely that those infected with cryptosporidium would be also infected
with other pathogens, and this might reduce the likelihood of efficacy in resolving
diarrhea.  But the results were very clear, cryptosporidium shedding was not reduced
by clofazimine. We clarified this in the discussion (p15).
Line 326- This could be expressed more clearly- are the authors saying that the
organism is exposed to the intraluminal CFZ and that efficacy may not be measured by
plasma levels or that the organism itself is impairing absorption of the drug?
Author response: We have clarified the sentence to state that the parasite may not be
well-exposed to intraluminal CFZ as it is located in a vacuole under the epithelial
plasma membrane and faces in towards the gut lumen (p15).
Table 2- would put the Number of subjects somewhere in the table
Author response: We include the number of subjects in the top row of the table (p32).
Reviewer #3: This report details the use of clofazimine for the treatment of
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cryptosporidiosis in persons with HIV. It was a two-part study with 20 persons enrolled
in a blinded, placebo-controlled RCT. Individuals randomized to active treatment with
clofazimine worsened during the trial with a > 2 log (100-fold) increase in parasite
excretion. 3 of 10 persons treated with CFZ died compared to 1 of 10 placebo treated
individuals. In the second part of the report, the authors report the pharmacokinetics of
CFZ in persons with HIV but without cryptosporidiosis. The report is well written.
Cryptosporidiosis in persons with HIV and low CD4 counts is often a lethal disease. No
direct, primary therapy has been shown to be effective in persons with HIV.
Nitazoxanide is of limited efficacy in persons without HIV, and of no proven benefit in
persons with HIV. The core of treatment of cryptosporidiosis in persons with advanced
HIV is prevention of death from dehydration and electrolyte disturbances while immune
reconstitution is attempted with antiviral therapy. Many reports from the advent of the
HIV pandemic described the extremely short life span of persons with untreated
cryptosporidiosis, often less than 2 weeks from the time of presentation.
Human subjects approval after IRB review was granted, and no ethical issues are
apparent. Many SAEs, including death, occurred in this population, and one person
who was treated with CFZ was reported by the site to have a medication-related SAE.
However, this was not upheld in review by the monitoring committee.
Dosing of clofazimine for the clinical trial was based upon the 'maximum given in
clinical practice' of 100 mgs thrice daily to adults > 50 kgs, or half that dose if < 50 kgs.
In the second part of the report, participants were matched to the active arm of the first
part of the trial based upon age, gender, and weight. Quantitative PCR was used to
assess excretion of the parasite, using first-passed-stool of the morning. In addition, all
stools were collected during an 8-hour periods during the 5 days of inpatient treatment.
The spectrum of Cryptosporidium species detected in participants included C. parvum,
C. hominis, C. meleagridis, the unusual species C. viatorum, and 3 of unknown
species.
Between 18 December 2017 and 14 February 2019, 5,790 persons were assessed for
eligibility. 494 were prescreened for Cryptosporidium in feces. 67 were positive and 22
were randomized to CFZ or placebo. Although 12 were randomized to CFZ, only 10
completed treatment, and 1 more person withdrew from the study during the outpatient
phase. Despite randomization, the active CFZ group was more male, had a lower BMI,
and indications of more serious infection with greater stool output weight, more
enteropathogens detected, and more advanced HIV (CD4 mean was ~ 25 compared to
~ 170 in the placebo group). Of importance, both the placebo and the active treatment
groups had high HIV viral loads indicating that their HIV antiviral therapy was not
effective.
Author response: We agree, we made these points in the body of the paper and have
now added these points to the abstract (p3-4).
In the CFZ and placebo groups, there was no significant change in stool weight,
frequency, consistency, or diarrhea grade during observation. In contrast, in the CFZ
group, CR shedding increased by two orders of magnitude (when measured per gram)
or in total calculated shedding (one order of magnitude). The graphs provided in the
manuscript are
Persons with cryptosporidiosis (Part A) had serum levels of CFZ that were about half of
those in persons without cryptosporidiosis (Part B) treated in the second phase of the
report.
The authors report that plasma levels of HIV drugs in Part A subjects were detected at
"similar" levels to Part B subjects suggesting they were compliant with their first-line
ARV therapy, and that ARV resistance "might be driving HIV treatment failure." This
suggests that the research team did not consider detecting, and addressing, ARV
resistance in the study protocol.
Author response: In planning this single center study, our preliminary data to inform the
design of the clinical trial did not include lab diagnostics, since standard lab tests such
as full blood count and comprehensive metabolic profiles are not always available nor
routinely done for patients hospitalized with diarrhea in Malawi, a setting with limited
resources. HIV care in Malawi, as evidenced by national guidelines, and clinical care in
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general, is guided by clinical presentation rather than by laboratory values. Therefore,
the research team was not aware of the extent of laboratory abnormalities that were
subsequently detected, including ARV resistance, among this patient population. When
HIV viral load results eventually became available, these results were reviewed by a
clinician and subjects were contacted and referred to HIV clinic to switch to second-line
ARV regimens. This is now stated in the discussion (p14).
This reviewer strongly objects to the data on HIV treatment and resistance not being
more forwardly placed in this report. First, HIV viral loads in the active treatment, and
placebo, groups were extremely high. Mean viral loads in the CFZ group were 2.4 x
105 and 6.8 x 105 in the placebo arm.  This is prima facie evidence that the antiviral
treatment the participants were taking were not active.  The core of treatment of
cryptosporidiosis in persons with HIV is the prevention of death while immune
reconstitution with antivirals is put in place. The authors do not state if a clinician
reviewed the CD4 count, and viral load data, and made the (elementary) assessment
that their treatment for HIV had failed. The authors do not state if the presence of a life-
threatening opportunistic infection prompted a review of the participant's medical
therapy and a change in their HIV antivirals because of presumptive resistance. While
this study was conducted in a resource-challenged developing country, these basic
assessments of HIV treatment adequacy were available and easily interpretable.
Author response: We agree with the reviewer that this is an important point of the
paper, and we have tried hard in the revision to bring out this point. To bring it forward
even more, we have added these issues to the abstract (p3-4).  As stated above, one
of the challenges of conducting a clinical trial such as this in a low-resource setting is
that the full extent of health status of these patients did not become apparent until
diagnostic testing was provided as a part of this trial. The research team did review all
laboratory results, including CD4 count and viral load, and followed up with subjects in
person to communicate these results to them and also to refer them to HIV clinic if
warranted. We have revised the discussion to address these concerns (p14).
This report clarifies that clofazimine, at the doses administered, achieved a serum level
in persons with ineffective antiviral therapy that was half that of persons with well-
controlled HIV. It clarifies that clofazimine had no evident positive effect in persons with
essentially untreated HIV. The mean viral load for participants in the Part B portion of
the study was 2.6 x 102, a thousandth that of the persons who received clofazimine in
the Part A portion of the study. Three-fold differences in viral loads are considered of
clinical significance.
Key questions about this study are entangled around the inadequacy of treatment for
HIV. It is possible that clofazimine, when administered to persons whose HIV is well
treated (as demonstrated by a low viral load), might have a therapeutic effect. The fact
that serum levels in persons with well-suppressed HIV were twice as high suggests
that in the setting of Cryptosporidium infection, the drug was not as well absorbed. This
would not be surprising given the architectural and functional changes seen in persons
with active cryptosporidiosis.
Author response: We have added these points in the discussion (p16).
The authors note that the parasite replicates within a parasitophorous vacuole which
may be difficult to drive CFZ into. It is no doubt all the more difficult to achieve CFZ
levels in such a location in the range desired when baseline absorption is poor. An
intravenous form of clofazimine was described in the past and the authors do not
discuss whether or not such a formulation would have been a better choice in this pilot
study. It
could be argued that in this clinical setting, oral and not iv therapy is appropriate to
study, but this reviewer believes the authors must address this issue.
Author response: Intravenous CFZ was not a formulation offered by our supplier and
therefore was not considered for this trial. In addition, an intravenous preparation of
CFZ would not be available to repurpose for use in outpatients infected with
cryptosporidium.  We have included these points in the discussion (p16).
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We thank you for your consideration.
Yours sincerely,
Pui-Ying Iroh Tam, MD, FAAP, FPIDS, FIDSA
Site Principal Investigator, CRYPTOFAZ
Head, Paediatrics and Child Health Research Group, Malawi-Liverpool Wellcome Trust
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William A. Petri, MD 
Associate Editor, Clinical Infectious Diseases 
 
5 March 2020 
 
Dear Dr. Petri, 
 
Thank you for considering our original study titled: “Clofazimine for treatment of 
cryptosporidiosis in HIV-infected adults (CRYPTOFAZ): an experimental medicine, 
randomised, double-blind, placebo-controlled phase 2a trial” for publication in Clinical 
Infectious Diseases. We also thank the reviewers for their thoughtful comments, and believe 
the revised manuscript has been improved as a result. Below we have listed our response to 
reviewer comments: 
 
Reviewer #1: Drugs to treat Cryptosporidiosis in severely immunocompromised patients, 
particularly those with HIV/AIDS, are not available and are urgently needed. This study was an 
attempt to see whether an existing drug, Clofazamine (CFZ), which has given very promising 
results in animal models, would be effective in this population. 
 
There are clearly issues with this trial. Recruitment proved unexpectedly difficult, which resulted 
in smaller treatment and control groups than the authors wanted, although they reached  the 
sample size (10 in each group) that they calculated would have sufficient power to give an 80% 
chance of detecting a significant difference between the groups. And, despite randomisation, 
the two groups turned out to be very different in many important parameters. 
 
I have one small change that I would like to see in the manuscript. On page 4 of the 
Supplementary appendix (1.6) we are told that calf data suggested that 10 persons in each arm 
would give adequate power to this trial. We are not given a reference to the calf data; I think 
we should see that and the numerical data that went into the power calculation. 
 
Author response: The calf data showing partial, limited efficacy of CFZ is in the 
process of being written up.  Therefore, in the Supplementary Appendix we have 
clarified this as ‘unpublished data, Michael Riggs, University of Arizona’ 
(Supplementary Appendix, p4). 
 
The lack of benefit from CFZ will be disappointing to many and the problems with this trial 
suggest that it won't be the last word on the subject, but the apparent dis-benefit of the drug 
on parasite excretion in the treatment group (although non-significant) will increase 
confidence in the author's conclusions. 
 
Author response: Thank you, we agree.  
 
Reviewer #2: This is a well-written manuscript reflecting a carefully performed study in an 
extremely ill patient population comparing clofazamine to placebo in HIV-associated 
cryptosporidial diarrheal disease. Unfortunately, by chance apparently, the randomization did 
not produce groups that were comparable in a number of important metrics- most notably 
CD4 count, symptom severity and number of co-pathogens that could cause diarrhea. The 
Response to Reviewers
 2 
authors present data that attempt to make a conclusive case that clofazimine was not 
efficacious - for example the trajectories of diarrhea severity, stool weight and consistency as 
well as organism burden over time. These are fairly convincing that clofazamine had no 
efficacy but because the clofazamine arm was sicker at baseline it is difficult to be completely 
convinced that this study is conclusive. 
 
The authors could possibly bolster the argument that there was no efficacy of clofazamine 
despite the poorer baseline status of the clofazamine arm. For example, were the stool co-
pathogens treated and if so, was there followup testing to document clearance of these 
pathogens or any time between the treatment of co-pathogens and the beginning of the study? 
It would be reassuring that the poor outcomes in the CFZ group were not attributable to these 
infections rather than lack of efficacy of clofazamine. 
 
Author response: Subjects hospitalized with symptomatic diarrhea were managed 
by the clinical team and treated with ciprofloxacin, which is the standard of care. The 
stool TaqMan assay results were not performed in real-time and therefore results 
were not available until after conclusion of the study. We clarified this in the 
discussion (p15).  Also it should be noted that the primary outcome was a change in 
cryptosporidium excretion, and not change in diarrhea.  We have clarified this in the 
discussion also (p15). 
 
I think it is important to detail the inclusion criteria in the primary manuscript rather than the 
supplementary materials- for example, the reader should be aware that part A participants 
were already on antiretroviral therapy and only needed to have diarrhea for 3 days to qualify. 
Also that part B participants were matched by age, gender and weight but not HIV disease 
stage. 
 
Author response: We have included eligibility criteria in the primary manuscript (p5). 
The Part B matching information is listed on p6 L126.  
 
For clarity: 
Line 209- please clarify if these differences between the groups were statistically significant. 
 
Author response: Since we used a randomized study design, which is the gold 
standard to ensure equal distribution between groups, we did not conduct statistical 
analysis to compare differences. In addition, the group sizes are really too small to 
infer statistical significance. We expect that if the trial had continued to recruit 
subjects, the resulting groups would be large enough that such differences as what 
we observed would be negligible.  
 
The fatalities- it would be helpful to briefly describe these in the main manuscript- it appears 
that none were felt by the DSMB to be related to the study drug but rather due to the severe 
underlying illnesses these patients all had. Describing them as "AEs with fatal outcome" implies 
they were from the trial- that may be required language that I'm unaware of. 
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Author response: We have briefly summarized these fatalities in the main 
manuscript (p11).  
 
The Tables should have some indication of which of the characteristics were significantly 
different between the groups- in footnotes or bolded values for example. 
 
Author response: Since we used a randomized study design, which is the gold 
standard to ensure equal distribution between study groups, we did not conduct 
statistical analysis to compare differences. Furthermore, the group sizes are really too 
small to infer statistical significance. Therefore, we presented the data as collected.  
 
Figures: Would spell out Change from Baseline 
 
Author response: Due to Figure size limitations we did not spell out Change from 
Baseline on the actual figure, but the abbreviation is spelt out in the figure legend 
(p18-19).  
 
Line 300: I'm not sure I understand this paragraph- why would you screen for diarrhea to 
predict people at risk for TB and ARV failure? 
 
Author response: Malawi is a resource-limited setting where HIV viral loads and CD4 
counts are not routinely done. Therefore, care is usually provided based on clinical 
presentation. Based on our findings in the study population, we suggest using 
presence of diarrhea as a screening proxy for HIV-infected immunosuppressed 
individuals at higher risk for TB and ARV failure. We have clarified this in the 
Supplementary Appendix (Supplementary p3). 
 
Line 316: This is the first we learn that the authors believe that Cryptosporidium was not 
driving diarrhea in up to 7 of the participants- which group did these participants fall into? 
How does that effect their assertion that CFZ was not efficacious? Line 320 and 321-do the 
authors believe that cryptosporidium was not responsible for the diarrhea in those who did not 
meet the cutoffs? 
 
Author response: On L216-217 we stated that the CFZ group has “more pathogens 
detected at higher quantities (67% v. 30%), and clarified in the same paragraph 
(L330-334) the issue of GEMS diarrheagenic amounts. We have re-organized the 
paragraph so that the information is clearer (p10).  However, please note the primary 
efficacy outcome was reduction in cryptosporidium shedding and not diarrhea 
resolution.  We knew that it was likely that those infected with cryptosporidium 
would be also infected with other pathogens, and this might reduce the likelihood of 
efficacy in resolving diarrhea.  But the results were very clear, cryptosporidium 
shedding was not reduced by clofazimine. We clarified this in the discussion (p15).  
 
Line 326- This could be expressed more clearly- are the authors saying that the organism is 
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exposed to the intraluminal CFZ and that efficacy may not be measured by plasma levels or 
that the organism itself is impairing absorption of the drug? 
 
Author response: We have clarified the sentence to state that the parasite may not 
be well-exposed to intraluminal CFZ as it is located in a vacuole under the epithelial 
plasma membrane and faces in towards the gut lumen (p15).  
 
Table 2- would put the Number of subjects somewhere in the table 
 
Author response: We include the number of subjects in the top row of the table 
(p32).  
 
Reviewer #3: This report details the use of clofazimine for the treatment of cryptosporidiosis in 
persons with HIV. It was a two-part study with 20 persons enrolled in a blinded, placebo-
controlled RCT. Individuals randomized to active treatment with clofazimine worsened during 
the trial with a > 2 log (100-fold) increase in parasite excretion. 3 of 10 persons treated with 
CFZ died compared to 1 of 10 placebo treated individuals. In the second part of the report, the 
authors report the pharmacokinetics of CFZ in persons with HIV but without cryptosporidiosis. 
The report is well written. 
 
Cryptosporidiosis in persons with HIV and low CD4 counts is often a lethal disease. No direct, 
primary therapy has been shown to be effective in persons with HIV. Nitazoxanide is of limited 
efficacy in persons without HIV, and of no proven benefit in persons with HIV. The core of 
treatment of cryptosporidiosis in persons with advanced HIV is prevention of death from 
dehydration and electrolyte disturbances while immune reconstitution is attempted with 
antiviral therapy. Many reports from the advent of the HIV pandemic described the extremely 
short life span of persons with untreated cryptosporidiosis, often less than 2 weeks from the 
time of presentation. 
 
Human subjects approval after IRB review was granted, and no ethical issues are apparent. 
Many SAEs, including death, occurred in this population, and one person who was treated with 
CFZ was reported by the site to have a medication-related SAE. However, this was not upheld 
in review by the monitoring committee. 
 
Dosing of clofazimine for the clinical trial was based upon the 'maximum given in clinical 
practice' of 100 mgs thrice daily to adults > 50 kgs, or half that dose if < 50 kgs. In the second 
part of the report, participants were matched to the active arm of the first part of the trial 
based upon age, gender, and weight. Quantitative PCR was used to assess excretion of the 
parasite, using first-passed-stool of the morning. In addition, all stools were collected during an 
8-hour periods during the 5 days of inpatient treatment. The spectrum of Cryptosporidium 
species detected in participants included C. parvum, C. hominis, C. meleagridis, the unusual 
species C. viatorum, and 3 of unknown species. 
 
Between 18 December 2017 and 14 February 2019, 5,790 persons were assessed for eligibility. 
494 were prescreened for Cryptosporidium in feces. 67 were positive and 22 were randomized 
to CFZ or placebo. Although 12 were randomized to CFZ, only 10 completed treatment, and 1 
more person withdrew from the study during the outpatient phase. Despite randomization, the 
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active CFZ group was more male, had a lower BMI, and indications of more serious infection 
with greater stool output weight, more enteropathogens detected, and more advanced HIV 
(CD4 mean was ~ 25 compared to ~ 170 in the placebo group). Of importance, both the 
placebo and the active treatment groups had high HIV viral loads indicating that their HIV 
antiviral therapy was not effective. 
 
Author response: We agree, we made these points in the body of the paper and 
have now added these points to the abstract (p3-4). 
 
In the CFZ and placebo groups, there was no significant change in stool weight, frequency, 
consistency, or diarrhea grade during observation. In contrast, in the CFZ group, CR shedding 
increased by two orders of magnitude (when measured per gram) or in total calculated 
shedding (one order of magnitude). The graphs provided in the manuscript are 
Persons with cryptosporidiosis (Part A) had serum levels of CFZ that were about half of those in 
persons without cryptosporidiosis (Part B) treated in the second phase of the report. 
The authors report that plasma levels of HIV drugs in Part A subjects were detected at "similar" 
levels to Part B subjects suggesting they were compliant with their first-line ARV therapy, and 
that ARV resistance "might be driving HIV treatment failure." This suggests that the research 
team did not consider detecting, and addressing, ARV resistance in the study protocol. 
 
Author response: In planning this single center study, our preliminary data to inform 
the design of the clinical trial did not include lab diagnostics, since standard lab tests 
such as full blood count and comprehensive metabolic profiles are not always 
available nor routinely done for patients hospitalized with diarrhea in Malawi, a 
setting with limited resources. HIV care in Malawi, as evidenced by national 
guidelines, and clinical care in general, is guided by clinical presentation rather than 
by laboratory values. Therefore, the research team was not aware of the extent of 
laboratory abnormalities that were subsequently detected, including ARV resistance, 
among this patient population. When HIV viral load results eventually became 
available, these results were reviewed by a clinician and subjects were contacted and 
referred to HIV clinic to switch to second-line ARV regimens. This is now stated in the 
discussion (p14).  
 
This reviewer strongly objects to the data on HIV treatment and resistance not being more 
forwardly placed in this report. First, HIV viral loads in the active treatment, and placebo, 
groups were extremely high. Mean viral loads in the CFZ group were 2.4 x 105 and 6.8 x 105 in 
the placebo arm.  This is prima facie evidence that the antiviral treatment the participants were 
taking were not active.  The core of treatment of cryptosporidiosis in persons with HIV is the 
prevention of death while immune reconstitution with antivirals is put in place. The authors do 
not state if a clinician reviewed the CD4 count, and viral load data, and made the (elementary) 
assessment that their treatment for HIV had failed. The authors do not state if the presence of a 
life-threatening opportunistic infection prompted a review of the participant's medical therapy 
and a change in their HIV antivirals because of presumptive resistance. While this study was 
conducted in a resource-challenged developing country, these basic assessments of HIV 
treatment adequacy were available and easily interpretable. 
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Author response: We agree with the reviewer that this is an important point of the 
paper, and we have tried hard in the revision to bring out this point. To bring it 
forward even more, we have added these issues to the abstract (p3-4).  As stated 
above, one of the challenges of conducting a clinical trial such as this in a low-
resource setting is that the full extent of health status of these patients did not 
become apparent until diagnostic testing was provided as a part of this trial. The 
research team did review all laboratory results, including CD4 count and viral load, 
and followed up with subjects in person to communicate these results to them and 
also to refer them to HIV clinic if warranted. We have revised the discussion to 
address these concerns (p14).  
 
This report clarifies that clofazimine, at the doses administered, achieved a serum level in 
persons with ineffective antiviral therapy that was half that of persons with well-controlled HIV. 
It clarifies that clofazimine had no evident positive effect in persons with essentially untreated 
HIV. The mean viral load for participants in the Part B portion of the study was 2.6 x 102, a 
thousandth that of the persons who received clofazimine in the Part A portion of the study. 
Three-fold differences in viral loads are considered of clinical significance. 
 
Key questions about this study are entangled around the inadequacy of treatment for HIV. It is 
possible that clofazimine, when administered to persons whose HIV is well treated (as 
demonstrated by a low viral load), might have a therapeutic effect. The fact that serum levels 
in persons with well-suppressed HIV were twice as high suggests that in the setting of 
Cryptosporidium infection, the drug was not as well absorbed. This would not be surprising 
given the architectural and functional changes seen in persons with active cryptosporidiosis.   
 
Author response: We have added these points in the discussion (p16). 
 
The authors note that the parasite replicates within a parasitophorous vacuole which may be 
difficult to drive CFZ into. It is no doubt all the more difficult to achieve CFZ levels in such a 
location in the range desired when baseline absorption is poor. An intravenous form of 
clofazimine was described in the past and the authors do not discuss whether or not such a 
formulation would have been a better choice in this pilot study. It 
could be argued that in this clinical setting, oral and not iv therapy is appropriate to study, but 
this reviewer believes the authors must address this issue. 
 
Author response: Intravenous CFZ was not a formulation offered by our supplier 
and therefore was not considered for this trial. In addition, an intravenous 
preparation of CFZ would not be available to repurpose for use in outpatients 
infected with cryptosporidium.  We have included these points in the discussion 
(p16). 
 
 
We thank you for your consideration. 
 
Yours sincerely, 
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Abstract 47 
Background: We evaluated efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in 48 
HIV-infected patients with cryptosporidiosis. 49 
 50 
Methods: We performed a randomized, double-blind, placebo-controlled study. Primary 51 
outcomes in Part A were reduction in Cryptosporidium shedding, safety, and PK. Primary 52 
analysis was according to protocol (ATP). Part B of the study compared CFZ PK in matched 53 
HIV-infected individuals without cryptosporidiosis. 54 
 55 
Results: Twenty Part A and 10 Part B participants completed the study ATP. Almost all Part A 56 
participants had high viral loads and low CD4 counts, consistent with failure of antiretroviral 57 
(ARV) therapy. At study entry, the Part A CFZ group had higher Cryptosporidium shedding, 58 
total stool weight, and more diarrheal episodes compared to the placebo group. Over the 59 
inpatient period, compared to those who received placebo, the CFZ group Cryptosporidium 60 
shedding increased by 2.17 log2 Cryptosporidium per gram stool (95% upper confidence limit: 61 
3.82), total stool weight decreased by 45.3 g (p=0.37), and number of diarrheal episodes 62 
increased by 2.32 (p=0.87). The most frequent solicited adverse effects were diarrhea, abdominal 63 
pain, and malaise. Three CFZ and 1 placebo subjects died during the study. Plasma levels of 64 
CFZ in participants with cryptosporidiosis were 2-fold lower than Part B controls.  65 
 66 
Conclusion: Our findings do not support the efficacy of CFZ for the treatment of 67 
cryptosporidiosis in a severely immunocompromised HIV population. However, this trial 68 
demonstrates a pathway to assess the therapeutic potential of drugs for cryptosporidiosis 69 
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treatment. Screening persons with HIV for diarrhea, and especially Cryptosporidium infection, 70 
may identify those failing ARV therapy. 71 
 72 
 73 
 74 
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Introduction  93 
Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in 94 
persons with HIV and also in young children in the developing world [1]. In children, 95 
cryptosporidiosis causes severe diarrhea [2], malabsorption and intestinal injury [3], excess 96 
mortality [2, 4], stunting and is associated with malnutrition [5]. There is a huge unmet need for 97 
Cryptosporidium drugs [6]: only nitazoxanide is licensed for treatment of cryptosporidiosis, but 98 
it has not shown any benefits as a treatment for HIV-infected and immunocompromised patients 99 
with cryptosporidiosis compared to placebo [7-9]. 100 
 101 
Clofazimine (CFZ), used for treatment of leprosy for more than 50 years, and currently part of 102 
treatment for multi-drug resistant TB, has recently been described as effective against 103 
Cryptosporidium in vitro [10]. The efficacy and pharmacokinetics (PK) of CFZ in HIV-infected 104 
patients with cryptosporidiosis are not known. We developed an experimental medicine study 105 
design to evaluate the safety, tolerability, PK and efficacy of CFZ in HIV-infected adults with 106 
cryptosporidiosis. 107 
 108 
Methods 109 
 110 
Study design and participants 111 
The study was a single center, randomized, double-blind, placebo-controlled Phase 2a two-part 112 
study at Queen Elizabeth Central Hospital in Blantyre, Malawi. Participants were eligible for 113 
Part A if they were HIV-infected, aged 18-65 years, weight over 35·4 kg, on antiretrovirals 114 
(ARV) for at least 1 month, and with diarrhea duration of minimum 14 days. Participants for Part 115 
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B were HIV-infected without diarrhea or Cryptosporidium, and met none of the exclusion 116 
criteria. Full criteria are listed in the Supplementary Appendix. The study protocol was approved 117 
by the relevant regulatory and ethics committees before study initiation [11]. Participants 118 
provided written informed consent.  119 
 120 
Study treatment and procedures 121 
Part A participants were randomized 1:1 to receive either five days of oral CFZ or placebo, 122 
respectively (Figure 1). The dosage of CFZ administered was the maximum given in clinical 123 
practice, 100 mg three times daily if ≥50 kg or 50 mg three times daily for subjects <50 kg [12].  124 
Participants for Part B were matched 1:1 to the first ten Part A subjects based on age (±5 years), 125 
gender, and weight (≥ or <50 kg; Supplementary Appendix).  126 
 127 
We used a rapid diagnostic test (RDT) for Cryptosporidium screening (prototype 128 
immunochromatographic test strip for detecting Cryptosporidium, TechLabs Inc., Blacksburg, 129 
VA, USA) and an ELISA stool test (CRYPTOSPORIDIUM II™, TechLabs Inc.) for assessing 130 
Cryptosporidium shedding in serial stools during the trial. All Cryptosporidium shedding was 131 
confirmed and measured by qPCR, with a positive result being a cycle threshold (Ct) <35. The 132 
first collected stool of the day was obtained throughout the dosing and follow-up periods, for 133 
testing of the Cryptosporidium ELISA signal, as well as for measurement of Cryptosporidium 134 
shedding by qPCR. In addition, all stools were collected and pooled in 8-hour intervals during 135 
the inpatient phase of the study, Days -1 to 5 of dosing. Thus, total Cryptosporidium stool 136 
excretion was measured by qPCR during this time.   137 
 138 
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Stool enteropathogens present at baseline in addition to Cryptosporidium were detected using 139 
qPCR in a TaqMan Array Card (TAC, Thermo Fisher, Waltham, MA, USA) using a custom 140 
design developed at the Houpt Laboratory (Charlottesville, VA, USA; Supplementary Appendix) 141 
[13]. Measurements of anti-retroviral (ARV) levels in plasma and alteration after administration 142 
of CFZ were evaluated in the Van Voorhis/Arnold Laboratories (Seattle, WA, USA). 143 
Measurement of CFZ concentration in plasma and stool were performed at Q2 Solutions (Ithaca, 144 
NY, USA).  145 
 146 
After the 5-day inpatient study drug dosing, with daily clinical examination and laboratory 147 
sampling, all participants entered a 2 month follow-up period that included a visit 19-24 days 148 
post last dose, and a final visit 41-55 days post last dose. During each visit and with weekly 149 
phone calls, participants were monitored for safety and symptoms. Safety labs were repeated if 150 
there were any abnormalities previously. If participants could not be reached by phone, home 151 
visits were made.  152 
 153 
Outcomes 154 
There were two primary endpoints for Part A: the first was efficacy, assessed as reduction in the 155 
(log) number of Cryptosporidium shed in the first collected stool of each study dosing day of 156 
CFZ vs. placebo recipients in subjects treated according to protocol (ATP). The second primary 157 
endpoint was safety, including frequency and severity of solicited and unsolicited adverse events 158 
(AEs), serious adverse events (SAEs), adverse events of special interest and suspected, 159 
unexpected serious adverse reactions. Part B had two primary endpoints (CFZ in plasma, and 160 
total daily amount of CFZ eliminated in stool) to meet a single primary PK objective. Secondary 161 
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endpoints were the reduction in the (log2) number of Cryptosporidium shed in stool compared to 162 
controls in the intention-to-treat (ITT) population, reduction in total daily Cryptosporidium 163 
shedding in those treated ATP, and as compared to controls in the ITT population, and reduction 164 
in severity of diarrhea over the study dosing period compared to controls.  165 
 166 
An independent data safety monitoring board (DSMB) was involved in regular review of blinded 167 
safety data to monitor risks and benefits and to assess any potential safety issues arising during 168 
the study. Trial site monitoring of participant safety was carried out by the sponsor medical 169 
monitor, an independent local safety monitor, the contract research organization medical 170 
monitor, and overseen by the chief investigator (WVV). This study is registered with 171 
ClinicalTrials.gov, number NCT03341767. 172 
 173 
Statistical analyses 174 
As the Phase 2a study was exploratory, we initially planned an interim analysis after 20 subjects 175 
were randomized and treated ATP; this sample size was predicted to detect a therapeutic 176 
difference based on animal data from molecular endpoints. Due to slow enrollment, it was 177 
decided to convert the interim analysis to a final analysis (Supplementary Appendix).  178 
 179 
The primary ATP analysis was performed using the randomized population who received at least 180 
80% of scheduled doses, completed daily assessments of fecal shedding, and had no major 181 
protocol deviations. When missing data for the primary endpoint (log number of 182 
Cryptosporidium shed per gram stool) was not attributable to non-detectable Cryptosporidium 183 
(i.e. no stooling), multiple imputation was utilized (Supplementary Appendix).  184 
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 185 
The safety population consisted of all subjects that received at least one dose of study drug. The 186 
PK population consisted of all subjects who had at least one measurable PK concentration 187 
(Supplementary Appendix).  188 
 189 
Due to the exploratory nature of the trial, no adjustments due to multiple testing were made; all 190 
statistical tests were performed with a one-sided alpha of 0.05. Statistical analyses were 191 
conducted using SAS version 9.3. 192 
 193 
Results 194 
Between 18 December 2017 and 14 February 2019, 5,790 adults were approached to assess 195 
eligibility. For randomization to CFZ vs. placebo (Part A), 494 were prescreened for 196 
Cryptosporidium presence in stool via RDT and qPCR, 67 participants were Cryptosporidium 197 
PCR-positive in stool and screened, and 22 were randomized (12 to CFZ and 10 to placebo, ITT 198 
group; Figure 1). Twenty subjects completed inpatient dosing ATP. There was one voluntary 199 
withdrawal (CFZ group) during the outpatient phase. There was no loss to follow-up.  200 
 201 
The RDT and ELISA stool test had low sensitivity (41% for both) to identify participants and 202 
follow the presence/absence of Cryptosporidium over time, compared with qPCR. The 203 
Cryptosporidium spp. identified were C. parvum (11/22, 50%), C. meleagridis (4/22, 18%), C. 204 
hominis (3/22, 14%), C. viatorum (1/22, 5%) and 3 unknowns. Coinfection of stool with multiple 205 
diarrhea enteropathogens was common, with a median of 4 co-pathogens (excluding 206 
Cryptosporidium) per subject (range 1-8).  The most frequently identified co-pathogen was 207 
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enteroaggregative E. coli (64%), followed by Shigella toxin-positive enterotoxigenic E. coli 208 
(41%) and Shigella/enteroinvasive E. coli (23%). The baseline characteristics of participants are 209 
listed in Table 1. Despite randomization, compared to the placebo group the CFZ group had by 210 
chance: more males (67% vs. 20%), lower body mass index (16.3±1.7 vs. 18.0±3.1 kg/m2), 211 
increased diarrhea output total stool weight (320.3±214.6 vs. 245.8±299.4 g), more pathogens 212 
detected at a diarrheagenic amount per Global Enteric Multicenter Study (GEMS) criteria (67% 213 
vs. 30%) [14], more advanced HIV immunosuppression (CD4 counts 25.3±24.4 vs. 170.4±321.7 214 
cells/µL), and higher prevalence of C. parvum detected (58% vs. 40%).  215 
 216 
Findings were similar for both ATP and ITT populations (Supplementary Table 1), and the ATP 217 
efficacy results are reported here. Stool Cryptosporidium excretion was persistent among Part A 218 
subjects throughout observation (Supplementary Figures 1 and 2), even at 41-55 days after the 219 
last dose. There was no significant difference in Cryptosporidium shedding in the CFZ group 220 
compared to placebo (Figures 2A-B). There was a trend towards increased change-from-baseline 221 
in Cryptosporidium shedding in the first stool of the day in the CFZ-treated group vs. placebo, 222 
with a difference in means of 2.17 log2 Cryptosporidium per gram ([95% upper confidence limit 223 
(CL): 3.82]), and in total Cryptosporidium shedding with a difference of means of 1.02 log2 224 
Cryptosporidium ([95% upper CL: 2.50]); the opposite result expected if CFZ was efficacious. 225 
There was no significant change in diarrhea in the CFZ group compared to placebo, whether 226 
measured by total stool weight change-from-baseline, number of diarrheal episodes, stool 227 
consistency grade, or severity diarrhea grade (Figures 2C-F).   228 
 229 
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For the PK of CFZ in HIV-infected subjects without diarrhea or Cryptosporidium (Part B), 92 230 
were prescreened, 18 were screened, and 11 received CFZ, with one voluntary withdrawal during 231 
the inpatient phase. Part A subjects had about 2-fold less plasma exposure of CFZ than Part B 232 
subjects on day 5 (ratio AUC0-24: 0.607), and on day 1 of the inpatient dosing (ratio AUC0-24: 233 
0.478; Table 2, Figure 3; stool PK profiles are listed in Supplementary Appendix and 234 
Supplementary Figure 3).  235 
 236 
For safety, solicited AEs (Table 3) - expected in persons with diarrhea - were experienced by all 237 
subjects in both CFZ and placebo groups. There were higher numbers of solicited AEs 238 
experienced in the CFZ group for diarrhea (9 (75%) vs. 4 (40%) in placebo), abdominal pain (8 239 
(67%) vs. 7 (70%) in placebo), and malaise (6 (50%) vs. 3 (30%) in placebo), and more severe 240 
solicited AEs in the CFZ group (2 (17%)) than the placebo group (0 (0%); Supplementary 241 
Figures 4 and 5). No Part B subject experienced any solicited AE. The number of unsolicited 242 
AEs (Supplementary Table 2) was highest in the CFZ group (13 vs. 12 in placebo and 3 in Part 243 
B); the number of subjects who experienced AEs with fatal outcome was also higher in the CFZ 244 
group (3 (25%) vs. 1 (10%) in placebo and none in Part B). None of the fatalities were judged by 245 
the study medical monitors and DSMB to be CFZ-related (Supplementary Appendix).  246 
 247 
Discussion 248 
This is the first randomized, double-blind, placebo-controlled Phase 2a trial to evaluate CFZ for 249 
treatment of cryptosporidiosis in HIV-infected adults. The trial demonstrated that CFZ had no 250 
significant impact on Cryptosporidium shedding of the parasite, or on diarrheal episodes, stool 251 
weight, and consistency, compared to placebo. Evaluation of Cryptosporidium shedding in the 252 
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first stool of the day provided similar data to total daily Cryptosporidium shedding. The drug is 253 
generally well-tolerated. Four patients died, three of whom received CFZ and the fourth placebo. 254 
This rate of death was consistent with our a priori estimates and each case was reviewed by the 255 
independent DSMB. CFZ achieved 2-fold less plasma exposure among Part A subjects with 256 
diarrhea vs. Part B subjects without diarrhea.  257 
 258 
The trial did show that HIV-infected adults with ≥3 days of diarrhea consistently excreted 259 
Cryptosporidium in their stools, even when assayed up to 60 days after enrollment.  This 260 
demonstrates that this population would be appropriate to study the antiparasitic benefit of anti-261 
Cryptosporidium drugs that do not depend on the immune response. 262 
 263 
The trial did not show a reduction in Cryptosporidium excretion in this population treated with 264 
CFZ vs. placebo. This was the case whether one compared the Cryptosporidium excretion by 265 
qPCR as determined by the concentration in the first stool of the day, or by determining the total 266 
Cryptosporidium excreted per day. In fact, there was a non-significant trend towards slightly 267 
increased Cryptosporidium shedding in the CFZ group vs. the placebo, which was most evident 268 
at day 2 of study drug dosing. The trend towards increased shedding may reflect the more ill 269 
status of the CFZ subjects at baseline, as documented in their enrollment labs and health status. 270 
With a median HIV CD4 count of 23.5 cells/mm3 (IQR 11.75, 43.75) and viral load of 168,097.5 271 
copies/mL (IQR 94,044, 643,812.3), the mortality rate of 18% in the trial likely reflects 272 
advanced disease in our Part A cohort as a whole. 273 
 274 
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Within our cohort, compared to placebo, the CFZ group had more deaths, SAEs, and severe 275 
solicited AEs. All subjects with cryptosporidiosis reported the solicited AEs expected with CFZ, 276 
such as diarrhea, abdominal pain, malaise and nausea. However, these solicited AEs were 277 
present at baseline in Part A subjects, as might be expected in this population with 278 
cryptosporidiosis, and were universal in both treatment groups. There tended to be less solicited 279 
AEs over time, which correlated with less severity in diarrhea during the hospital phase, and the 280 
severity of AEs tended to decrease over time. None of the Part B subjects exposed to the same 281 
dose of CFZ reported solicited AEs, and only 3 Part B subjects reported unsolicited AEs, and 282 
these were generally mild.  283 
 284 
A previous clinical trial for cryptosporidiosis treatment identified multiple safety concerns 285 
related to the health status of participants. This Phase 1-2 trial of miltefosine to treat HIV-related 286 
cryptosporidiosis in Zambian adults with chronic diarrhea was terminated early due to high 287 
mortality, lack of efficacy and development of SAEs that were attributed to the extreme 288 
metabolic abnormalities already present in patients enrolled in the trial [15]. In our trial, subjects 289 
with cryptosporidiosis also presented with electrolyte abnormalities, most commonly 290 
hypokalemia that required correction, and some required corrective treatment through the trial. In 291 
addition, there was also a very high incidence of active TB in the HIV-infected screening 292 
population. Screening by chest x-ray was inadequate likely because dehydrated subjects often do 293 
not have an infiltrate until rehydrated. Screening of sputum by GeneXpert or gram stain also was 294 
inadequate due to inability of dehydrated subjects to produce sputum. All deaths in our study 295 
were reported prior to instituting urine LAM screening at baseline. Once urine LAM screening 296 
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was instituted [16], 43% of our otherwise eligible subjects subsequently tested positive by urine 297 
LAM and were excluded.  298 
 299 
Part A participants were extremely immunosuppressed. Most had CD4 counts <25 cells/µL and 300 
high HIV viral loads. Plasma levels of HIV medicines were detected at similar levels to Part B 301 
subjects (unpublished data), suggesting that these Part A subjects were compliant with first-line 302 
ARV therapy and that ARV resistance might be driving HIV treatment failure. Therefore, 303 
screening for diarrhea in this population, and especially for Cryptosporidium, delineated those 304 
more at risk for TB and ARV failure.  305 
 306 
The predominant Cryptosporidium species was C. parvum subtype family IIc anthroponotic 307 
(10/11, 91% of those with C. parvum). This was unexpected, given that the majority of 308 
Cryptosporidium species identified in the pediatric GEMS and adult studies were C. hominis [17-309 
20]. However, a high prevalence of C. parvum has been noted in HIV/AIDS patients in Ethiopia, 310 
where 92/140 (66%) of HIV/AIDS patients were positive by PCR-RFLP [21]. As C. parvum has 311 
been associated with prolonged diarrhea in HIV-positive persons more frequently than C. 312 
hominis [17] the trial inclusion criteria may have selected for this species.  313 
 314 
Multiple copathogens were observed in stool, which may have contributed to the diarrhea [3], 315 
but patients with symptomatic diarrhea were routinely treated with ciprofloxacin as standard of 316 
care. Cryptosporidium may have driven the diarrhea in at least 15 of 22 subjects in this trial, as it 317 
was the pathogen with the lowest Ct value, and may have been the pathogen in the greatest 318 
quantity shed in stool. After applying GEMS cutoffs, which use Ct counts to determine clinically 319 
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relevant diarrhea [14], only 7 Cryptosporidium samples met diarrheagenic cutoffs, and only 11 320 
samples met diarrheagenic pathogen criteria. As GEMS data were based on children, the lack of 321 
correlation between Ct value and clinical diarrhea likely reflects the differences seen in an adult 322 
population with severe HIV immunosuppression with prolonged diarrhea.  323 
 324 
Our PK data suggests that diarrhea and/or Cryptosporidium infection negatively impacts CFZ 325 
plasma exposure. Since efficacy is likely driven by CFZ levels in the parasite, which may not be 326 
well-exposed to intraluminal CFZ as it is located in a vacuole under the epithelial plasma 327 
membrane, and faces in towards the gut lumen [22], plasma levels may not reflect efficacy as it 328 
would for systemic infections. The fact that serum CFZ levels in persons with well-suppressed 329 
HIV were twice as high suggests that in the setting of Cryptosporidium infection, the drug was 330 
not well absorbed. We propose that lower levels of CFZ likely exist in the epithelium layer in the 331 
Part A subjects, as passage through the gastrointestinal epithelium is required for access to the 332 
plasma. These lower levels may have contributed to the failure of efficacy against 333 
Cryptosporidium. However, we used the maximum dosage of CFZ that is accepted as safe in this 334 
trial [12], therefore increasing the dosage to improve efficacy may not be feasible. An 335 
intravenous form of clofazimine, described in the past [23], may have provided better systemic 336 
delivery of the drug; however, this was not a formulation available at the time of the trial.  337 
 338 
One of the limitations of the study was the small sample size. This led to slightly uneven 339 
randomization (12 vs. 10) based on block size. Also, imbalances in the baseline characteristics 340 
were noted in the Part A subjects CFZ vs. placebo groups, with the CFZ group being more ill at 341 
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baseline. One possible confounder was the presence of multiple co-pathogens in the stool, which 342 
could have influenced diarrhea resolution.  343 
 344 
For the conduct of future human experimental trials of cryptosporidiosis in this population, this 345 
study suggests that: 1) the screening population should be evaluated for TB detection, through 346 
urine LAM, and for electrolyte disturbances, particularly hypokalemia; 2) use of stool RDT in 347 
screening and ELISA tests on serial stools is not as sensitive as qPCR, and that we need only use 348 
qPCR to enroll and follow participants for Cryptosporidium excretion over time; 3) following 349 
serial Cryptosporidium shedding by qPCR of the first stool of the day, rather than total stool 350 
collection, is probably sufficient to assess efficacy; 4) given the ill status of enrolled subjects, an 351 
inpatient trial is merited and AEs and deaths may complicate safety evaluation of new study 352 
drugs; and 5) future trials would need to be multisite given the slow recruitment rate. There was, 353 
until this trial, few placebo-controlled trials in adults [24-26] and limited data on how to test the 354 
drugs in Phase 2a. This trial shows that HIV-infected adults with cryptosporidiosis excrete the 355 
parasite consistently and thus the effects of treatment on excretion would be a feasible way to 356 
monitor for efficacy in Cryptosporidium therapy.  357 
 358 
In conclusion, this is the first controlled clinical trial to assess the safety, efficacy, and PK of 359 
CFZ for treatment of cryptosporidiosis. Although CFZ does not show promise as a novel 360 
therapeutic for Cryptosporidium infection, future human studies can use an approach based on 361 
lessons learned in this trial to assess the therapeutic potential of drugs for treatment of 362 
cryptosporidiosis.   363 
 364 
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Table 1. Baseline characteristics of participants  568 
Characteristic Part A CFZ group 
(n=12) 
Part A placebo 
group (n=10) 
Part B CFZ 
group (n=11) 
Age, years  39.8 (7.8) 39.1 (12.0) 44.1 (9.6) 
Male sex (%) 8 (67%) 2 (20%) 7 (64%) 
BMI, kg/m2  16.3 (1.7) 18.0 (3.1) 18.9 (1.4) 
Pulse rate, beats/min 90.9 (12.4) 95.9 (14.9) 78.1 (6.7) 
Systolic blood pressure, 
mmHg 
99.3 (15.0) 106.4 (16.5) 116.5 (11.8) 
Diastolic blood pressure, 
mmHg 
68,3 (10.1) 71.2 (8.8) 75.7 (12.3) 
Hemoglobin, g/dL 10.6 (2.2) 10.8 (2.8) 14.0 (1.3) 
Hematocrit, % 32.3 (6.5) 32.6 (8.7) 42.3 (3.6) 
White blood cells, 109/L 2.9 (1.4) 3.8 (2.8) 5.0 (1.7) 
Neutrophils, 109/L 1.6 (0.9) 2.1 (2.1) 2.5 (1.2) 
Lymphocytes, 109/L 0.8 (0.5) 1.1 (0.7) 2.0 (0.8) 
CD4 absolute, cells/µL    
Mean (SD) 25.3 (24.4) 170.4 (321.7) 422.0 (231.3) 
Median (IQR) 23.0 (8.0, 32.0) 22.5 (17.0, 86.0) 361.0  
(216.0, 634.0) 
HIV viral load, copies/µL  241,981.5 
(262,806.03) 
679,025.13 
(929,116.49) 
257.5 (805.7) 
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ARV duration, days  1424 (1547.6) 2011 (1409.3) 1265 (1810.3) 
Blood urea nitrogen, 
mmol/L 
4.9 (2.5) 3.9 (1.1) 3.8 (1.0) 
Creatinine, µmol/L 82.0 (37.2) 56.0 (15.9) 65.4 (14.0) 
Alanine aminotransferase, 
IU/L 
34.0 (20.3) 40.3 (19.5) 38.9 (21.4) 
Aspartate aminotransferase, 
IU/L 
50.6 (16.4) 63.0 (30.4) 50.7 (18.3) 
Electrocardiogram (ECG)    
Normal (%) 11 (92%) 10 (100%) 11 (100%) 
Abnormal, not clinically 
significant (%) 
1 (8%) 0 (0%) 0 (0%) 
QTc interval, ms 421.7 (14.2) 418.3 (17.0) 409.7 (21.6) 
Cryptosporidium spp. (%)    
C. parvum 7 (58%) 4 (40%) N/A 
C. hominis 2 (17%) 1 (10%) N/A 
C. meleagridis 1 (8%) 3 (30%) N/A 
C. viatorum 1 (8%) 0 (0%) N/A 
Unknowna 1 (8%) 2 (20%) N/A 
Co-pathogens detected at 
diarrheagenic amount [14] 
(%) 
8 (67%) 3 (30%) N/A 
 28 
Diarrhea duration,b days 17 (7.6) 34 (57) N/A 
Stool ELISA positivity 
(D1, %) 
7 (58%) 2 (20%) N/A 
Log number of 
cryptosporidium shed in 
first collected stool of day, 
Cryptosporidium per gram 
stool (D-1) 
13.9 (2.7) 15.0 (2.2) N/A 
Total daily cryptosporidium 
shedding, Cryptosporidium 
per gram stool (D-1) 
22.3 (2.9) 22.1 (3.2) N/A 
Total stool weight, g (D-1) 320.3 (214.6) 245.8 (299.4) N/A 
Most severe diarrhea 
severity gradec (mild)  
9 (75%) 3 (30%) N/A 
Stool consistency severity 
grade ≥3 (D-1, %) 
9 (75%) 6 (67%) N/A 
Number of diarrheal 
episodes,c D1 
1.3 (1.1) 0.8 (1.3) N/A 
ARV, antiretroviral therapy; BMI, body mass index; D, day; IQR, interquartile range; SD, 569 
standard deviation 570 
All values are mean (SD) unless otherwise listed. 571 
aFailed to amplify on sequencing of 18s and gp60. 572 
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bSubjects with diarrhea duration entries ‘>2 weeks’ were treated as 21 days for calculations of 573 
summary statistics. 574 
cObserved over the first 24-hour dosing interval after the first study dose.  575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
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Table 2. Comparison of pharmacokinetic parameters in Part A and B subjects 596 
PK parameter Part A (n=12) Part B (n=11) 
Mean (SD) % CV Mean (SD) % CV 
Day 1 Cmin (ng/mL) 35.83 (37.28) 323 74.74 (24.51) 46 
 Cmax (ng/mL) 97.55 (117.9) 195 193.3 (93.50) 58 
 Tmax (h) 19.73 (5.67) - 14.776 (7.537) - 
 AUC0-24 (ng.h/mL) 1364.0 (1754.0) 219 2851.0 (1256.0) 50 
Day 5 Cmin (ng/mL) 258.8 (353.1) 187 455.8 (221.5) 47 
 Cmax (ng/mL) 280.7 (355.2) 173 514.1 (202.0) 39 
 Tmax (h) 9.679 (10.81) - 6.683 (3.765) - 
 AUC0-24 (ng.h/mL) 6863.0 (8552.0) 172 11298.0 (5580.0) 59 
Summary t1/2 (h)
a 336.5 (84.71) 25 535.5 (4.950) 1 
 RAUC 5.905 (3.516) 57 4.111 (1.579) 50 
AUC, area under the curve; Cmax, peak plasma concentration; Cmin, trough plasma 597 
concentration; CV, coefficient of variation; RAUC, accumulation ratio for AUC0-24 for Day 5 to 598 
Day 1; SD, standard deviation; Tmax, time to reach Cmax; t1/2, elimination half-life 599 
aElimination half-life of clofazimine was previously found to be up to 70 days upon repeat dose 600 
administration [27]; therefore the relatively short plasma sampling schedule in this study may not 601 
be accurately capture the t1/2 parameter in these populations. 602 
 603 
 604 
 605 
 606 
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Table 3. Summary of adverse events 607 
  Part A – CFZ 
(n=12) 
Part A – 
placebo (n=10) 
Part B (n=11) 
Any solicited 
adverse event  
Any severity 12 (100%) 10 (100%) 0 (0%) 
Max severity 2 (17%) 0 (0%) 0 (0%) 
Abdominal pain  Any severity 8 (67%) 7 (70%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Vomiting  Any severity 4 (33%) 4 (40%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Diarrhea  Any severity 9 (75%) 4 (40%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
Anorexia  Any severity 4 (33%) 3 (30%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
Skin 
discoloration 
Any severity 0 (0%) 0 (0%) 0 (0%) 
Nausea Any severity 5 (42%) 5 (50%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Malaise Any severity 6 (50%) 3 (30%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0(0%) 
Urgency of 
defecation 
Any severity 5 (42%) 4 (40%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
Any adverse events with fatal 
outcome 
3 (25%) 1 (10%) 0 (0%) 
 32 
Number of unsolicited adverse 
events 
13 12 3 
Subjects with at least one 
unsolicited adverse event 
6 (50%) 4 (40%) 3 (27%) 
Subjects with a serious adverse 
event  
5 (42%) 2 (20%) 0 (0%) 
Any unsolicited adverse event 
related to study drug 
2 (17%) 0 (0%) 3 (27%) 
Any unsolicited adverse event 
leading to discontinuation of study 
drug  
0 (0%) 1 (10%) 0 (0%) 
 608 
 609 
 610 
Figure 1 Click here to access/download;Figure (.tif and .eps files
only);Figure 1-CONSORT DIAGRAM_v2.3_25Dec19.tiff
Figure 2 Click here to access/download;Figure (.tif and .eps files
only);Figure 2_CFZ efficacy ATP_03Oct19.tiff
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1. Methods 
 
1.1 Study design  
The study was a single center, randomized, double-blind, placebo-controlled Phase 2a two-
part study at Queen Elizabeth Central Hospital in Blantyre, Malawi. Subjects were screened 
at this government, tertiary-level hospital, which serves the Southern region of the country, 
and were also referred from surrounding health centers within the Blantyre district. The study 
protocol and relevant supporting materials were approved by the National Health Sciences 
Research Committee (NHSRC) and the Pharmacy, Medicines, and Poisons Board in Malawi, 
and the Liverpool School of Tropical Medicine research ethics committee before study 
initiation.1 Participants provided written informed consent. The NHSRC set participant 
compensation levels were used. 
 
1.2 Participants 
Participants were eligible for Part A if they met the following inclusion criteria: HIV-
infected, aged 18-65 years, weight over 35·4 kg, on antiretrovirals (ARV) for at least 1 
month, and with diarrhea duration of minimum 14 days. We estimated a priori a death rate in 
the HIV population in Malawi to be approximately 15%. Recruitment commenced on 18 
December, 2017. On 6 April, 2018 after five subjects were randomized, eligibility criteria 
were amended to include participants with diarrhea duration of a minimum of 3 days and who 
have been on ARV for a minimum two weeks. Criteria were amended due to slow 
recruitment. Exclusion criteria included fever; evidence of active tuberculosis (by chest x-ray, 
sputum positive for TB by GeneXpert or Acid Fast Bacilli, and after 13 subjects were 
randomized, positive urine lipoarabinomannan (LAM)); history of allergy or hypersensitivity 
to CFZ; significant cardiac arrhythmia or ECG abnormalities; history of additional risk 
factors for Torsade de Pointes; family history of long QT syndrome; use of concomitant 
medications that markedly prolong the QT interval; pregnant and lactating women; use of 
systemic corticosteroids or anti-Cryptosporidial treatments within the preceding 28 days; and 
subjects with clinically significant laboratory value abnormalities at screening (hemoglobin 
<5 g/dL, serum potassium <3·0 mEq/L, and aspartate aminotransferase (AST) or alanine 
transaminase (ALT) ≥3 times upper limit of normal).  
 
Participants for Part B were HIV-infected without diarrhea or Cryptosporidium, met none of 
the exclusion criteria, and were matched 1:1 to the first ten Part A subjects based on age (±5 
years), gender, and weight (≥ or <50 kg).  
 
1.3 Randomization and masking 
We used a computer-generated randomization schedule where Part A group assignments of 
CFZ (Lamprene®, Novartis, Switzerland) and placebo were allocated in a 1:1 ratio, 
respectively, using a permuted block design with block size 4. Randomization was done by a 
contracted third-party contract research organization (CRO, Emmes, Rockville, MD, USA) 
that were involved in oversight but not the day-to-day clinical management of the study. The 
study drug and placebo were identical in appearance. Only the Emmes statisticians 
conducting the analysis and the pharmacists who prepared the pill packs were unmasked. The 
investigators, participants, and study site personnel involved in treating and assessing 
participants were masked to treatment allocation until the data was locked to further changes. 
 
1.4 Procedures 
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Enrolled participants received five days of oral CFZ 50 mg three times daily for subjects <50 
kg, or 100 mg three times daily if ≥50 kg, or placebo, respectively. Each dose was given half 
an hour after consumption of a fortified peanut-based paste (Plumpy Nut®, Nutriset, France). 
Participants were hospitalized for the five days of the study drug administration and returned 
on site for two follow-up visits. Laboratory testing was primarily carried out on-site at the 
Malawi-Liverpool Wellcome Trust Clinical Research Programme (MLW) laboratories. We 
used a rapid diagnostic test (RDT) for Cryptosporidium screening (prototype 
immunochromatographic test strip for detecting Cryptosporidium, TechLabs Inc., 
Blacksburg, VA, USA) and an ELISA stool test (CRYPTOSPORIDIUM II™, TechLabs 
Inc.) for quantifying Cryptosporidium shedding in serial stools during the trial. All 
Cryptosporidium shedding was confirmed and measured by qPCR, with a positive result 
being a cycle threshold (Ct) <35. The first collected stool of the day was obtained throughout 
the dosing and follow-up periods, for testing of the Cryptosporidium ELISA signal, as well as 
for measurement of Cryptosporidium shedding by qPCR. In addition, all stools were 
collected and pooled in 8-hour intervals during the inpatient phase of the study, Days -1 to 5 
of dosing. Thus, total Cryptosporidium stool excretion was measured by qPCR during this 
time.   
 
Stool enteropathogens present at baseline in addition to Cryptosporidium were detected using 
qPCR in a TaqMan Array Card (TAC, Thermo Fisher, Waltham, MA, USA) using a custom 
design developed at the Houpt Laboratory (Charlottesville, VA, USA).2 TAC assays were 
performed at MLW, and also included previously published qPCR assays that distinguished 
C. hominis and C. parvum.3 Further characterization of Cryptosporidium from baseline 
samples was achieved using Sanger sequencing targeting the 18S4 and gp60 genes5 
performed at the Houpt Laboratory. The primer pairings originally described in Glaberman et 
al.5 for the amplification of gp60 prior to Sanger sequencing were modified such that 5’-
ATAGTCTCCGCTGTATTC-3’ was paired with 5’-GGAAGGAACGATGTATCT-3’ for 
the primary amplification and 5’-TCCGCTGTATTCTCAGCC-3’ was paired with 5’-
GCAGAGGAACCAGCATC-3’ for the secondary nested amplification. Measurements of 
ARV levels in plasma and alteration after administration of CFZ were evaluated in the Van 
Voorhis/Arnold Laboratories (Seattle, WA, USA). Measurement of CFZ concentration in 
plasma and stool were performed at Q2 Solutions (Ithaca, NY, USA) using liquid 
chromatography-tandem mass spectrometry (LC/MS/MS), which were validated for 
quantification of CFZ within the range of 1·0-1000 ng/mL in human plasma.  
 
After study drug dosing, all participants entered a follow-up period of two months that 
included a follow-up visit within 19-24 days post last dose, and a final visit 41-55 days post 
last dose. During each follow-up visit and with weekly phone calls, participants were 
monitored for safety and symptoms. Blood and stool specimens were collected at each visit, 
and safety labs were repeated if there were any abnormalities previously. If participants could 
not be reached by phone, home visits were made.  
 
In a resource-limited setting such as Malawi, laboratory investigations are not always 
available and therefore clinical care is primarily reliant on clinical presentation and 
symptoms. As part of the clinical care, laboratory results were reviewed by a clinician and 
subjects were referred for additional care as needed. 
 
1.5 Outcomes 
There were two primary endpoints for Part A, though formal statistical testing was only 
utilized for the primary efficacy endpoint. The first primary endpoint was efficacy, assessed 
 4 
as reduction in the (log) number of Cryptosporidium shed in the first collected stool of each 
study dosing day of CFZ vs. placebo recipients in subjects treated according to protocol 
(ATP). The second primary endpoint was safety, based on safety assessments collected 
throughout dosing and follow-up periods, and consisted of frequency and severity of solicited 
and unsolicited adverse events (AEs) through study product administration, including serious 
adverse events (SAEs), adverse events of special interest (AESIs) and suspected, unexpected 
serious adverse reactions (SUSARs). Part B had two primary endpoints (CFZ in plasma, and 
total daily amount of CFZ eliminated in stool) to meet a single primary PK objective.  
 
Secondary endpoints were the reduction in the (log2) number of Cryptosporidium shed in 
stool compared to controls in the intention-to-treat (ITT) population, reduction in total daily 
Cryptosporidium shedding in those treated ATP, and as compared to controls in the ITT 
population, and reduction in severity of diarrhea over the study dosing period compared to 
controls.  
 
1.6 Statistical analyses 
Calf data on fecal shedding over time (unpublished data, Michael Riggs, University of 
Arizona) suggested that 10 individuals treated in each arm would be sufficient to give a 
>80% chance of seeing a difference with an efficacious drug . We were uncertain about the 
relevance of the animal data to the HIV subjects, and whether they would have consistent 
shedding over the period of treatment. Thus, we arbitrarily increased the sample size to 28 
per group.  
 
As the Phase 2a study was exploratory, we initially planned an interim analysis after 20 
subjects were randomized and treated ATP. Due to slow enrollment, it was decided to 
convert the interim analysis to a final analysis.  
 
Efficacy endpoints for Part A were summarized descriptively, and continuous efficacy 
variables were summarized at baseline and in terms of change from baseline at each day 
following study drug administration. The primary ATP analysis was performed using the 
randomized population who received at least 80% of scheduled doses, completed daily 
assessments of fecal shedding, and had no major protocol deviations. When missing data for 
the primary endpoint (log number of Cryptosporidium shed per gram stool) was not 
attributable to non-detectable Cryptosporidium (i.e. no stooling), multiple imputation was 
utilized. The fully conditional specification (FCS) method for arbitrary longitudinal missing 
data patterns was used to perform multiple imputation of the missing primary efficacy 
variable as well as any missing covariates. Mixed ANCOVA models for repeated measures 
were used to model and analyze the difference, between treatment groups, in the change from 
baseline in continuous endpoints over the inpatient period, and generally included baseline 
response, day, and treatment group as covariates. Gender and age were also included as 
covariates in models for the log number of cryptosporidium shed in the first collected stool 
(analyzed in the ATP and ITT populations). The day by treatment interaction term was 
considered for inclusion in models if statistically significant, and if included, the difference in 
efficacy measures in the last inpatient day was reported. Proportional odds models were used 
for the analysis of categorical endpoints (e.g., stool consistency and diarrhea severity). Upper 
95% confidence intervals (CI) and p-values were derived from each model.  
 
The safety population consisted of all subjects that received at least one dose of study drug. 
All safety analyses were descriptive. Ten subjects enrolled in Part B were matched to the first 
10 subjects who completed Part A ATP, to develop a comparative description of the 
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absorption and excretion of the drug in the two groups. The PK population consisted of all 
subjects who had at least one measurable PK concentration. Plasma and stool drug 
concentrations were plotted at each timepoint for matched Part A and Part B subjects 
together, on linear scale. PK parameters were estimated through a non-compartmental 
analysis using Phoenix WinNonlin version 8.0 or later (Pharsight Corporation, Cary, NC, 
USA). The paired t-test was used to assess differences between groups for each PK parameter 
on days 1 and 5 (Cmin, Cmax, and AUC0-24), and reported the geometric mean ratio between 
groups. We reported the Hodges-Lehmann estimator (pseudomedian) for the difference in 
each parameter between Part A and Part B subjects. P-values and 95% CI for each of the 
above tests were calculated.  
 
Due to the exploratory nature of the trial, no adjustments due to multiple testing were made; 
all statistical tests were performed with a one-sided alpha of 0.05. Statistical analyses were 
conducted using SAS version 9.3. 
 
To maximize the safety and integrity of the study, an independent data safety monitoring 
board (DSMB) was involved in regular review of blinded safety data to monitor risks and 
benefits and to assess any potential safety issues arising during the study. Trial site 
monitoring of participant safety was carried out by the sponsor medical monitor, an 
independent local safety monitor, the CRO medical monitor, and overseen by the chief 
investigator (WVV). This study is registered with ClinicalTrials.gov, number NCT03341767. 
 
1.7 Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The first and last authors (PI, WVV) and the funders 
had full access to all the data in the study, following data lock. The first and last authors were 
responsible for the decision to submit for publication. 
 
2. Results 
 
2.1 Stool PK profiles 
The total observed daily amount of CFZ eliminated in the feces on days 2 and 5 was not 
significantly different between Part A and B subjects (Supplementary Figure 3). Less than 
2% of the cumulative CFZ doses was recovered in stool in both groups over the five days of 
stool collection.  
 
2.2 Fatal outcomes 
Two CFZ-treated subjects developed a fatal sepsis-like syndrome on day 5 of dosing. The 
first, judged to be unrelated to study drug, developed severe fatigue on the morning of the last 
dosing day with documented hypotension and was judged to have sepsis, received ceftriaxone 
and intravenous fluids, but rapidly died despite therapy. The second fatal case occurred in a 
subject who developed abdominal pains a day after receipt of CFZ, resolved when CFZ was 
stopped, then recurred when CFZ was restarted. An abdominal ultrasound demonstrated 
biliary stones, but a surgical consult could not be organized before the subject died of sepsis-
like syndrome. The site judged the death to be related to CFZ administration, although the 
study medical monitors and DSMB judged this fatal SAE to be unrelated. The third CFZ-
treated subject that died presented to the hospital with profound hypotension and diarrhea on 
day 18 after receipt of study drug. The patient did not respond to fluid resuscitation in the 
emergency suite and expired quickly after arrival. Death was attributed to the effects of 
chronic diarrhea, AIDS, and delayed presentation. The fatal SAE in the placebo group 
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occurred 47 days after study drug administration, in a subject who had been diagnosed with 
pulmonary and extrapulmonary TB after randomization with rehydration. The latter two 
deaths were judged not to be related to treatment. No autopsies were conducted in any of the 
deaths so exact causes of death could not be ascribed. 
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Supplementary Table 1. Efficacy of clofazimine compared to placebo in the according to 
protocol (ATP) and intention-to-treat (ITT) populations 
 
Outcomes Difference in 
means 
95% upper 
confidence 
limit 
P-
value 
Parasitologic 
Change from baseline in log2 number of 
cryptosporidium shed in first collected stool (log2 
Cryptosporidium per gram), ATP 
2·17 3·82 0·984 
Change from baseline in log2 number of 
cryptosporidium shed in first collected stool (log2 
Cryptosporidium per gram), ITT 
1·73 3·13 0·977 
Change from baseline in total daily 
cryptosporidium shedding (log2 Cryptosporidium), 
ATP 
1·02 2·50 0·877 
Change from baseline in total daily 
cryptosporidium shedding (log2 Cryptosporidium), 
ITT 
0·16 1·69 0·569 
Diarrheal 
Change from baseline in total stool weight at Day 
5 (g), ATP 
132·05 314·48 0·888 
Change from baseline in total stool weight at Day 
5 (g), ITT 
-45·30 179·88 0·366 
Number of diarrheal episodes, ATP 1·92 5·73 0·802 
Number of diarrheal episodes, ITT 2·32 5·74 0·871 
Characteristics Odds ratio   
Most severe stool consistency grade, ATP 0·66 10·39 0·401 
Most severe stool consistency grade, ITT 1·85 26·26 0·651 
Most severe diarrhea grade, ATP 5·33 29·28 0·947 
Most severe diarrhea grade, ITT 4·87 23·85 0·950 
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Supplementary Table 2. Total number of unsolicited adverse events 
 
  Part A – 
CFZ 
(n=12) 
Part A – 
placebo 
(n=10) 
Part B 
(n=11) 
MedDRA system organ 
class 
MedDRA preferred 
term 
No. of 
events 
No. of 
events 
No. of 
events 
Any system organ class Any preferred term 13 12 3 
Blood and lymphatic 
system disorders 
Anemia 0 3 0 
Gastrointestinal disorders Any preferred term 4 0 0 
 Abdominal pain 1 0 0 
 Anal fissure 1 0 0 
 Diarrhea 2 0 0 
General disorders and 
administration site 
conditions 
Pyrexia 0 1 0 
Infections and infestations Any preferred term 4 6 0 
 Extrapulmonary 
tuberculosis 
0 1 0 
 Gastroenteritis 1 1 0 
 Lower respiratory tract 
infection 
1 0 0 
 Esophageal 
candidiasis 
0 1 0 
 Oral candidiasis 0 1 0 
 Pneumonia 0 1 0 
 Pulmonary 
tuberculosis 
0 1 0 
 Sepsis 1 0 0 
 Septic shock 1 0 0 
Investigations Any preferred term 1 0 3 
 Alanine 
aminotransferase 
increased 
0 0 2 
 Neutrophil count 
decreased 
0 0 1 
 White blood cell count 
decreased 
1 0 0 
Metabolism and nutrition 
disorders 
Hypokalemia 1 1 0 
Skin and subcutaneous 
tissue disorders 
Decubitus ulcer 1 0 0 
Vascular disorders Any preferred term 2 1 0 
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 Hypotension 1 1 0 
 Hypovolemic shock 1 0 0 
CFZ, clofazimine; MedDRA, medical dictionary for regulatory activities 
 
 
Supplementary Figure 1. Treatment response in the intention-to-treat group:  
A) Mean change from baseline (CFB) in log2 number of cryptosporidium shed in first 
collected stool over time  
 
 
 
B) Mean CFB in total daily cryptosporidium shedding over time  
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C) Mean total daily cryptosporidium shedding over time  
 
 
 
D) Mean CFB in total stool weight over time 
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E) Mean number of diarrheal episodes over time  
 
 
 
F) Proportion of most severe stool consistency grade by time  
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G) Proportion of most severe diarrhea grade by time  
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Supplementary Figure 2. Stool cryptosporidium shedding in:  
A) First stool of the day 
 
 
 
B) Total daily stooling 
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Supplementary Figure 3. Mean amount of CFZ in stool by timepoint  
 
 
 
CFZ, clofazimine; D, day; GM, geometric mean; V, study visit 
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Supplementary Figure 4. Maximum severity of solicited symptoms 
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Supplementary Figure 5. Frequency of adverse events by organ class and:  
A) Severity 
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B) Relationship to treatment 
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1. Methods 
 
1.1 Study design  
The study was a single center, randomized, double-blind, placebo-controlled Phase 2a two-
part study at Queen Elizabeth Central Hospital in Blantyre, Malawi. Subjects were screened 
at this government, tertiary-level hospital, which serves the Southern region of the country, 
and were also referred from surrounding health centers within the Blantyre district. The study 
protocol and relevant supporting materials were approved by the National Health Sciences 
Research Committee (NHSRC) and the Pharmacy, Medicines, and Poisons Board in Malawi, 
and the Liverpool School of Tropical Medicine research ethics committee before study 
initiation.1 Participants provided written informed consent. The NHSRC set participant 
compensation levels were used. 
 
1.2 Participants 
Participants were eligible for Part A if they met the following inclusion criteria: HIV-
infected, aged 18-65 years, weight over 35·4 kg, on antiretrovirals (ARV) for at least 1 
month, and with diarrhea duration of minimum 14 days. We estimated a priori a death rate in 
the HIV population in Malawi to be approximately 15%. Recruitment commenced on 18 
December, 2017. On 6 April, 2018 after five subjects were randomized, eligibility criteria 
were amended to include participants with diarrhea duration of a minimum of 3 days and who 
have been on ARV for a minimum two weeks. Criteria were amended due to slow 
recruitment. Exclusion criteria included fever; evidence of active tuberculosis (by chest x-ray, 
sputum positive for TB by GeneXpert or Acid Fast Bacilli, and after 13 subjects were 
randomized, positive urine lipoarabinomannan (LAM)); history of allergy or hypersensitivity 
to CFZ; significant cardiac arrhythmia or ECG abnormalities; history of additional risk 
factors for Torsade de Pointes; family history of long QT syndrome; use of concomitant 
medications that markedly prolong the QT interval; pregnant and lactating women; use of 
systemic corticosteroids or anti-Cryptosporidial treatments within the preceding 28 days; and 
subjects with clinically significant laboratory value abnormalities at screening (hemoglobin 
<5 g/dL, serum potassium <3·0 mEq/L, and aspartate aminotransferase (AST) or alanine 
transaminase (ALT) ≥3 times upper limit of normal).  
 
Participants for Part B were HIV-infected without diarrhea or Cryptosporidium, met none of 
the exclusion criteria, and were matched 1:1 to the first ten Part A subjects based on age (±5 
years), gender, and weight (≥ or <50 kg).  
 
1.3 Randomization and masking 
We used a computer-generated randomization schedule where Part A group assignments of 
CFZ (Lamprene®, Novartis, Switzerland) and placebo were allocated in a 1:1 ratio, 
respectively, using a permuted block design with block size 4. Randomization was done by a 
contracted third-party contract research organization (CRO, Emmes, Rockville, MD, USA) 
that were involved in oversight but not the day-to-day clinical management of the study. The 
study drug and placebo were identical in appearance. Only the Emmes statisticians 
conducting the analysis and the pharmacists who prepared the pill packs were unmasked. The 
investigators, participants, and study site personnel involved in treating and assessing 
participants were masked to treatment allocation until the data was locked to further changes. 
 
1.4 Procedures 
Enrolled participants received five days of oral CFZ 50 mg three times daily for subjects <50 
kg, or 100 mg three times daily if ≥50 kg, or placebo, respectively. Each dose was given half 
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an hour after consumption of a fortified peanut-based paste (Plumpy Nut®, Nutriset, France). 
Participants were hospitalized for the five days of the study drug administration and returned 
on site for two follow-up visits. Laboratory testing was primarily carried out on-site at the 
Malawi-Liverpool Wellcome Trust Clinical Research Programme (MLW) laboratories. We 
used a rapid diagnostic test (RDT) for Cryptosporidium screening (prototype 
immunochromatographic test strip for detecting Cryptosporidium, TechLabs Inc., 
Blacksburg, VA, USA) and an ELISA stool test (CRYPTOSPORIDIUM II™, TechLabs 
Inc.) for quantifying Cryptosporidium shedding in serial stools during the trial. All 
Cryptosporidium shedding was confirmed and measured by qPCR, with a positive result 
being a cycle threshold (Ct) <35. The first collected stool of the day was obtained throughout 
the dosing and follow-up periods, for testing of the Cryptosporidium ELISA signal, as well as 
for measurement of Cryptosporidium shedding by qPCR. In addition, all stools were 
collected and pooled in 8-hour intervals during the inpatient phase of the study, Days -1 to 5 
of dosing. Thus, total Cryptosporidium stool excretion was measured by qPCR during this 
time.   
 
Stool enteropathogens present at baseline in addition to Cryptosporidium were detected using 
qPCR in a TaqMan Array Card (TAC, Thermo Fisher, Waltham, MA, USA) using a custom 
design developed at the Houpt Laboratory (Charlottesville, VA, USA).2 TAC assays were 
performed at MLW, and also included previously published qPCR assays that distinguished 
C. hominis and C. parvum.3 Further characterization of Cryptosporidium from baseline 
samples was achieved using Sanger sequencing targeting the 18S4 and gp60 genes5 
performed at the Houpt Laboratory. The primer pairings originally described in Glaberman et 
al.5 for the amplification of gp60 prior to Sanger sequencing were modified such that 5’-
ATAGTCTCCGCTGTATTC-3’ was paired with 5’-GGAAGGAACGATGTATCT-3’ for 
the primary amplification and 5’-TCCGCTGTATTCTCAGCC-3’ was paired with 5’-
GCAGAGGAACCAGCATC-3’ for the secondary nested amplification. Measurements of 
ARV levels in plasma and alteration after administration of CFZ were evaluated in the Van 
Voorhis/Arnold Laboratories (Seattle, WA, USA). Measurement of CFZ concentration in 
plasma and stool were performed at Q2 Solutions (Ithaca, NY, USA) using liquid 
chromatography-tandem mass spectrometry (LC/MS/MS), which were validated for 
quantification of CFZ within the range of 1·0-1000 ng/mL in human plasma.  
 
After study drug dosing, all participants entered a follow-up period of two months that 
included a follow-up visit within 19-24 days post last dose, and a final visit 41-55 days post 
last dose. During each follow-up visit and with weekly phone calls, participants were 
monitored for safety and symptoms. Blood and stool specimens were collected at each visit, 
and safety labs were repeated if there were any abnormalities previously. If participants could 
not be reached by phone, home visits were made.  
 
In a resource-limited setting such as Malawi, laboratory investigations are not always 
available and therefore clinical care is primarily reliant on clinical presentation and 
symptoms. As part of the clinical care, laboratory results were reviewed by a clinician and 
subjects were referred for additional care as needed. 
 
1.5 Outcomes 
There were two primary endpoints for Part A, though formal statistical testing was only 
utilized for the primary efficacy endpoint. The first primary endpoint was efficacy, assessed 
as reduction in the (log) number of Cryptosporidium shed in the first collected stool of each 
study dosing day of CFZ vs. placebo recipients in subjects treated according to protocol 
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(ATP). The second primary endpoint was safety, based on safety assessments collected 
throughout dosing and follow-up periods, and consisted of frequency and severity of solicited 
and unsolicited adverse events (AEs) through study product administration, including serious 
adverse events (SAEs), adverse events of special interest (AESIs) and suspected, unexpected 
serious adverse reactions (SUSARs). Part B had two primary endpoints (CFZ in plasma, and 
total daily amount of CFZ eliminated in stool) to meet a single primary PK objective.  
 
Secondary endpoints were the reduction in the (log2) number of Cryptosporidium shed in 
stool compared to controls in the intention-to-treat (ITT) population, reduction in total daily 
Cryptosporidium shedding in those treated ATP, and as compared to controls in the ITT 
population, and reduction in severity of diarrhea over the study dosing period compared to 
controls.  
 
1.6 Statistical analyses 
Calf data on fecal shedding over time (unpublished data, Michael Riggs, University of 
Arizona) suggested that 10 individuals treated in each arm would be sufficient to give a 
>80% chance of seeing a difference with an efficacious drug. We were uncertain about the 
relevance of the animal data to the HIV subjects, and whether they would have consistent 
shedding over the period of treatment. Thus, we arbitrarily increased the sample size to 28 
per group.  
 
As the Phase 2a study was exploratory, we initially planned an interim analysis after 20 
subjects were randomized and treated ATP. Due to slow enrollment, it was decided to 
convert the interim analysis to a final analysis.  
 
Efficacy endpoints for Part A were summarized descriptively, and continuous efficacy 
variables were summarized at baseline and in terms of change from baseline at each day 
following study drug administration. The primary ATP analysis was performed using the 
randomized population who received at least 80% of scheduled doses, completed daily 
assessments of fecal shedding, and had no major protocol deviations. When missing data for 
the primary endpoint (log number of Cryptosporidium shed per gram stool) was not 
attributable to non-detectable Cryptosporidium (i.e. no stooling), multiple imputation was 
utilized. The fully conditional specification (FCS) method for arbitrary longitudinal missing 
data patterns was used to perform multiple imputation of the missing primary efficacy 
variable as well as any missing covariates. Mixed ANCOVA models for repeated measures 
were used to model and analyze the difference, between treatment groups, in the change from 
baseline in continuous endpoints over the inpatient period, and generally included baseline 
response, day, and treatment group as covariates. Gender and age were also included as 
covariates in models for the log number of cryptosporidium shed in the first collected stool 
(analyzed in the ATP and ITT populations). The day by treatment interaction term was 
considered for inclusion in models if statistically significant, and if included, the difference in 
efficacy measures in the last inpatient day was reported. Proportional odds models were used 
for the analysis of categorical endpoints (e.g., stool consistency and diarrhea severity). Upper 
95% confidence intervals (CI) and p-values were derived from each model.  
 
The safety population consisted of all subjects that received at least one dose of study drug. 
All safety analyses were descriptive. Ten subjects enrolled in Part B were matched to the first 
10 subjects who completed Part A ATP, to develop a comparative description of the 
absorption and excretion of the drug in the two groups. The PK population consisted of all 
subjects who had at least one measurable PK concentration. Plasma and stool drug 
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concentrations were plotted at each timepoint for matched Part A and Part B subjects 
together, on linear scale. PK parameters were estimated through a non-compartmental 
analysis using Phoenix WinNonlin version 8.0 or later (Pharsight Corporation, Cary, NC, 
USA). The paired t-test was used to assess differences between groups for each PK parameter 
on days 1 and 5 (Cmin, Cmax, and AUC0-24), and reported the geometric mean ratio between 
groups. We reported the Hodges-Lehmann estimator (pseudomedian) for the difference in 
each parameter between Part A and Part B subjects. P-values and 95% CI for each of the 
above tests were calculated.  
 
Due to the exploratory nature of the trial, no adjustments due to multiple testing were made; 
all statistical tests were performed with a one-sided alpha of 0.05. Statistical analyses were 
conducted using SAS version 9.3. 
 
To maximize the safety and integrity of the study, an independent data safety monitoring 
board (DSMB) was involved in regular review of blinded safety data to monitor risks and 
benefits and to assess any potential safety issues arising during the study. Trial site 
monitoring of participant safety was carried out by the sponsor medical monitor, an 
independent local safety monitor, the CRO medical monitor, and overseen by the chief 
investigator (WVV). This study is registered with ClinicalTrials.gov, number NCT03341767. 
 
1.7 Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The first and last authors (PI, WVV) and the funders 
had full access to all the data in the study, following data lock. The first and last authors were 
responsible for the decision to submit for publication. 
 
2. Results 
 
2.1 Stool PK profiles 
The total observed daily amount of CFZ eliminated in the feces on days 2 and 5 was not 
significantly different between Part A and B subjects (Supplementary Figure 3). Less than 
2% of the cumulative CFZ doses was recovered in stool in both groups over the five days of 
stool collection.  
 
2.2 Fatal outcomes 
Two CFZ-treated subjects developed a fatal sepsis-like syndrome on day 5 of dosing. The 
first, judged to be unrelated to study drug, developed severe fatigue on the morning of the last 
dosing day with documented hypotension and was judged to have sepsis, received ceftriaxone 
and intravenous fluids, but rapidly died despite therapy. The second fatal case occurred in a 
subject who developed abdominal pains a day after receipt of CFZ, resolved when CFZ was 
stopped, then recurred when CFZ was restarted. An abdominal ultrasound demonstrated 
biliary stones, but a surgical consult could not be organized before the subject died of sepsis-
like syndrome. The site judged the death to be related to CFZ administration, although the 
study medical monitors and DSMB judged this fatal SAE to be unrelated. The third CFZ-
treated subject that died presented to the hospital with profound hypotension and diarrhea on 
day 18 after receipt of study drug. The patient did not respond to fluid resuscitation in the 
emergency suite and expired quickly after arrival. Death was attributed to the effects of 
chronic diarrhea, AIDS, and delayed presentation. The fatal SAE in the placebo group 
occurred 47 days after study drug administration, in a subject who had been diagnosed with 
pulmonary and extrapulmonary TB after randomization with rehydration. The latter two 
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deaths were judged not to be related to treatment. No autopsies were conducted in any of the 
deaths so exact causes of death could not be ascribed. 
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Supplementary Table 1. Efficacy of clofazimine compared to placebo in the according to 
protocol (ATP) and intention-to-treat (ITT) populations 
 
Outcomes Difference in 
means 
95% upper 
confidence 
limit 
P-
value 
Parasitologic 
Change from baseline in log2 number of 
cryptosporidium shed in first collected stool (log2 
Cryptosporidium per gram), ATP 
2·17 3·82 0·984 
Change from baseline in log2 number of 
cryptosporidium shed in first collected stool (log2 
Cryptosporidium per gram), ITT 
1·73 3·13 0·977 
Change from baseline in total daily 
cryptosporidium shedding (log2 Cryptosporidium), 
ATP 
1·02 2·50 0·877 
Change from baseline in total daily 
cryptosporidium shedding (log2 Cryptosporidium), 
ITT 
0·16 1·69 0·569 
Diarrheal 
Change from baseline in total stool weight at Day 
5 (g), ATP 
132·05 314·48 0·888 
Change from baseline in total stool weight at Day 
5 (g), ITT 
-45·30 179·88 0·366 
Number of diarrheal episodes, ATP 1·92 5·73 0·802 
Number of diarrheal episodes, ITT 2·32 5·74 0·871 
Characteristics Odds ratio   
Most severe stool consistency grade, ATP 0·66 10·39 0·401 
Most severe stool consistency grade, ITT 1·85 26·26 0·651 
Most severe diarrhea grade, ATP 5·33 29·28 0·947 
Most severe diarrhea grade, ITT 4·87 23·85 0·950 
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Supplementary Table 2. Total number of unsolicited adverse events 
 
  Part A – 
CFZ 
(n=12) 
Part A – 
placebo 
(n=10) 
Part B 
(n=11) 
MedDRA system organ 
class 
MedDRA preferred 
term 
No. of 
events 
No. of 
events 
No. of 
events 
Any system organ class Any preferred term 13 12 3 
Blood and lymphatic 
system disorders 
Anemia 0 3 0 
Gastrointestinal disorders Any preferred term 4 0 0 
 Abdominal pain 1 0 0 
 Anal fissure 1 0 0 
 Diarrhea 2 0 0 
General disorders and 
administration site 
conditions 
Pyrexia 0 1 0 
Infections and infestations Any preferred term 4 6 0 
 Extrapulmonary 
tuberculosis 
0 1 0 
 Gastroenteritis 1 1 0 
 Lower respiratory tract 
infection 
1 0 0 
 Esophageal 
candidiasis 
0 1 0 
 Oral candidiasis 0 1 0 
 Pneumonia 0 1 0 
 Pulmonary 
tuberculosis 
0 1 0 
 Sepsis 1 0 0 
 Septic shock 1 0 0 
Investigations Any preferred term 1 0 3 
 Alanine 
aminotransferase 
increased 
0 0 2 
 Neutrophil count 
decreased 
0 0 1 
 White blood cell count 
decreased 
1 0 0 
Metabolism and nutrition 
disorders 
Hypokalemia 1 1 0 
Skin and subcutaneous 
tissue disorders 
Decubitus ulcer 1 0 0 
Vascular disorders Any preferred term 2 1 0 
 Hypotension 1 1 0 
 Hypovolemic shock 1 0 0 
CFZ, clofazimine; MedDRA, medical dictionary for regulatory activities 
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Supplementary Figure 1. Treatment response in the intention-to-treat group:  
A) Mean change from baseline (CFB) in log2 number of cryptosporidium shed in first 
collected stool over time  
 
 
 
B) Mean CFB in total daily cryptosporidium shedding over time  
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C) Mean total daily cryptosporidium shedding over time  
 
 
 
D) Mean CFB in total stool weight over time 
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E) Mean number of diarrheal episodes over time  
 
 
 
F) Proportion of most severe stool consistency grade by time  
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G) Proportion of most severe diarrhea grade by time  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
Supplementary Figure 2. Stool cryptosporidium shedding in:  
A) First stool of the day 
 
 
 
B) Total daily stooling 
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Supplementary Figure 3. Mean amount of CFZ in stool by timepoint  
 
 
 
CFZ, clofazimine; D, day; GM, geometric mean; V, study visit 
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Supplementary Figure 4. Maximum severity of solicited symptoms 
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Supplementary Figure 5. Frequency of adverse events by organ class and:  
A) Severity 
 
 
 
B) Relationship to treatment 
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Key points 24 
We evaluated clofazimine for treatment of adult HIV subjects with cryptosporidiosis. 25 
Clofazimine was well tolerated, but did not reduce Cryptosporidium excretion or diarrhea 26 
compared with subjects treated with placebo. This trial forms a blueprint for future 27 
cryptosporidiosis therapeutic trials. 28 
 29 
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 35 
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 40 
 41 
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Abstract 47 
Background: We evaluated efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in 48 
HIV-infected patients with cryptosporidiosis, a life-threatening infection without effective 49 
treatment for this population. 50 
 51 
Methods: We performed a randomized, double-blind, placebo-controlled study. Primary 52 
outcomes in Part A were reduction in Cryptosporidium shedding, safety, and PK. Primary 53 
analysis was according to protocol (ATP) with intention-to-treat as secondary analysis. Part B of 54 
the study compared the CFZ PK of CFZ in matched HIV-infected individuals without 55 
cryptosporidiosis (Clinicaltrials.gov #NCT03341767). 56 
 57 
Results: Twenty Part A and 10 Part B participants completed the study ATP. Almost all Part A 58 
participants had high viral loads and low CD4 counts, consistent with failure of antiretroviral 59 
(ARV) therapy. At study entry, the Part A CFZ group had higher Cryptosporidium shedding, 60 
total stool weight, and more diarrheal episodes compared to the placebo group. Over the 61 
inpatient period, compared to those who received placebo, the CFZ group Cryptosporidium 62 
shedding increased by 2.17 log2 Cryptosporidium per gram stool (95% upper confidence limit: 63 
3.82), total stool weight decreased by 45.3 g (p=0.37), and number of diarrheal episodes 64 
increased by 2.32 (p=0.87). The most frequent solicited adverse effects were diarrhea (9/12, 65 
75%), abdominal pain (8/12, 67%), and malaise (6/12, 50%). Three CFZ and 1 placebo subjects 66 
died during the study. Plasma levels of CFZ in participants with cryptosporidiosis were 2-fold 67 
lower than Part B controls. Part A subjects continued shedding Cryptosporidium up to 60 days 68 
after screening.  69 
 4 
 70 
Conclusion: Our findings do not support the efficacy of CFZ for the treatment of 71 
cryptosporidiosis in a severely immunocompromised HIV population. However, this trial 72 
demonstrates a pathway to assess the therapeutic potential of drugs for cryptosporidiosis 73 
treatment. Screening persons with HIV for diarrhea, and especially Cryptosporidium infection, 74 
may identify those failing ARV therapy. 75 
 76 
 77 
 78 
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 96 
Introduction  97 
Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in 98 
persons with HIV and also in young children in the developing world [1]. In children, 99 
cryptosporidiosis causes severe diarrhea [2], malabsorption and intestinal injury [3], excess 100 
mortality [2, 4], stunting and is associated with malnutrition [5]. To date, only nitazoxanide is 101 
licensed for treatment of cryptosporidiosis, but it has not shown any benefits as a treatment for 102 
HIV-infected and immunocompromised patients with cryptosporidiosis compared to placebo [6-103 
8]. Therefore, tThere is a huge unmet need for Cryptosporidium drugs [6]: only nitazoxanide is 104 
licensed for treatment of cryptosporidiosis, but it has not shown any benefits as a treatment for 105 
HIV-infected and immunocompromised patients with cryptosporidiosis compared to placebo [7-106 
9].. 107 
 108 
Clofazimine (CFZ), used for treatment of leprosy for more than 50 years, and currently part of 109 
treatment for multi-drug resistant TB, has recently been described as effective against 110 
Cryptosporidium in vitro , and was able to eliminate C. parvum in a mouse model [10]. CFZ has 111 
been in use for treatment of leprosy for more than 50 years, and is also used as part of a WHO 112 
regimen to treat multi-drug resistant Mycobacterium tuberculosis. The efficacy and 113 
pharmacokinetics (PK) of CFZ in HIV-infected patients with cryptosporidiosis are not known. 114 
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We developed an experimental medicine study design to evaluate the safety, tolerability, PK and 115 
efficacy of CFZ in HIV-infected adults with cryptosporidiosis. 116 
 117 
Methods 118 
 119 
Study design and participants 120 
The study was a single center, randomized, double-blind, placebo-controlled Phase 2a two-part 121 
study at Queen Elizabeth Central Hospital in Blantyre, Malawi. Participants were eligible for 122 
Part A if they were HIV-infected, aged 18-65 years, weight over 35·4 kg, on antiretrovirals 123 
(ARV) for at least 1 month, and with diarrhea duration of minimum 14 days. Participants for Part 124 
B were HIV-infected without diarrhea or Cryptosporidium, and met none of the exclusion 125 
criteria. Full inclusion and exclusion criteria for Part A and B participants are listed in the 126 
Supplementary Appendix. The study protocol and relevant supporting materials werewas 127 
approved by the relevant regulatory and ethics committees before study initiation [11]. 128 
Participants provided written informed consent.  129 
 130 
Study treatment and procedures 131 
Part A participants were randomized 1:1 to receive either five days of oral CFZ or placebo, 132 
respectively (Figure 1). The dosage of CFZ administered was the maximum given in clinical 133 
practice, 100 mg three times daily if ≥50 kg or 50 mg three times daily for subjects <50 kg [12].  134 
Participants for Part B were matched 1:1 to the first ten Part A subjects based on age (±5 years), 135 
gender, and weight (≥ or <50 kg; Supplementary Appendix).  136 
 137 
 7 
We used a rapid diagnostic test (RDT) for Cryptosporidium screening (prototype 138 
immunochromatographic test strip for detecting Cryptosporidium, TechLabs Inc., Blacksburg, 139 
VA, USA) and an ELISA stool test (CRYPTOSPORIDIUM II™, TechLabs Inc.) for assessing 140 
Cryptosporidium shedding in serial stools during the trial. All Cryptosporidium shedding was 141 
confirmed and measured by qPCR, with a positive result being a cycle threshold (Ct) <35. The 142 
first collected stool of the day was obtained throughout the dosing and follow-up periods, for 143 
testing of the Cryptosporidium ELISA signal, as well as for measurement of Cryptosporidium 144 
shedding by qPCR. In addition, all stools were collected and pooled in 8-hour intervals during 145 
the inpatient phase of the study, Days -1 to 5 of dosing. Thus, total Cryptosporidium stool 146 
excretion was measured by qPCR during this time.   147 
 148 
Stool enteropathogens present at baseline in addition to Cryptosporidium were detected using 149 
qPCR in a TaqMan Array Card (TAC, Thermo Fisher, Waltham, MA, USA) using a custom 150 
design developed at the Houpt Laboratory (Charlottesville, VA, USA; Supplementary Appendix) 151 
[13]. Measurements of anti-retroviral (ARV) levels in plasma and alteration after administration 152 
of CFZ were evaluated in the Van Voorhis/Arnold Laboratories (Seattle, WA, USA). 153 
Measurement of CFZ concentration in plasma and stool were performed at Q2 Solutions (Ithaca, 154 
NY, USA).  155 
 156 
After the 5-day inpatient study drug dosing, with daily clinical examination and laboratory 157 
sampling, all participants entered a two 2 month follow-up period that included a visit 19-24 158 
days post last dose, and a final visit 41-55 days post last dose. During each visit and with weekly 159 
phone calls, participants were monitored for safety and symptoms. Safety labs were repeated if 160 
 8 
there were any abnormalities previously. If participants could not be reached by phone, home 161 
visits were made.  162 
 163 
Outcomes 164 
There were two primary endpoints for Part A: the first was efficacy, assessed as reduction in the 165 
(log) number of Cryptosporidium shed in the first collected stool of each study dosing day of 166 
CFZ vs. placebo recipients in subjects treated according to protocol (ATP). The second primary 167 
endpoint was safety, and consisted ofincluding frequency and severity of solicited and 168 
unsolicited adverse events (AEs), including serious adverse events (SAEs), adverse events of 169 
special interest and suspected, unexpected serious adverse reactions. Part B had two primary 170 
endpoints (CFZ in plasma, and total daily amount of CFZ eliminated in stool) to meet a single 171 
primary PK objective. Secondary endpoints were the reduction in the (log2) number of 172 
Cryptosporidium shed in stool compared to controls in the intention-to-treat (ITT) population, 173 
reduction in total daily Cryptosporidium shedding in those treated ATP, and as compared to 174 
controls in the ITT population, and reduction in severity of diarrhea over the study dosing period 175 
compared to controls.  176 
 177 
An independent data safety monitoring board (DSMB) was involved in regular review of blinded 178 
safety data to monitor risks and benefits and to assess any potential safety issues arising during 179 
the study. Trial site monitoring of participant safety was carried out by the sponsor medical 180 
monitor, an independent local safety monitor, the contract research organization medical 181 
monitor, and overseen by the chief investigator (WVV). This study is registered with 182 
ClinicalTrials.gov, number NCT03341767. 183 
 9 
 184 
Statistical analyses 185 
As the Phase 2a study was exploratory, we initially planned an interim analysis after 20 subjects 186 
were randomized and treated ATP; this sample size was predicted to detect a therapeutic 187 
difference based on animal data from molecular endpoints. Due to slow enrollment, it was 188 
decided to convert the interim analysis to a final analysis (Supplementary Appendix).  189 
 190 
The primary ATP analysis was performed using the randomized population who received at least 191 
80% of scheduled doses, completed daily assessments of fecal shedding, and had no major 192 
protocol deviations. When missing data for the primary endpoint (log number of 193 
Cryptosporidium shed per gram stool) was not attributable to non-detectable Cryptosporidium 194 
(i.e. no stooling), multiple imputation was utilized (Supplementary Appendix).  195 
 196 
The safety population consisted of all subjects that received at least one dose of study drug. The 197 
PK population consisted of all subjects who had at least one measurable PK concentration 198 
(Supplementary Appendix).  199 
 200 
Due to the exploratory nature of the trial, no adjustments due to multiple testing were made; all 201 
statistical tests were performed with a one-sided alpha of 0.05. Statistical analyses were 202 
conducted using SAS version 9.3. 203 
 204 
Results 205 
 10 
In the Blantyre District of Malawi, bBetween 18 December 2017 and 14 February 2019, 5,790 206 
adults were approached to assess eligibility. For randomization to CFZ vs. placebo (Part A), 494 207 
were prescreened for Cryptospodiridium presence in stool via RDT and qPCR, 67 participants 208 
were Cryptosporidium PCR-positive in stool and screened, and 22 were randomized (12 to CFZ 209 
and 10 to placebo, ITT group; Figure 1). Twenty subjects completed inpatient dosing ATP. 210 
There was one voluntary withdrawal (CFZ group) during the outpatient phase. There was no loss 211 
to follow-up.  212 
 213 
The RDT and ELISA stool test had low sensitivity (41% for both) to identify participants and 214 
follow the presence/absence of Cryptosporidium over time, compared with qPCR. The 215 
Cryptosporidium spp. identified were C. parvum (11/22, 50%), C. meleagridis (4/22, 18%), C. 216 
hominis (3/22, 14%), C. viatorum (1/22, 5%) and 3 unknowns. Coinfection of stool with multiple 217 
diarrhea enteropathogens was common, with a median of 4 co-pathogens (excluding 218 
Cryptosporidium) per subject (range 1-8).  The most frequently identified co-pathogen was 219 
enteroaggregative E. coli (64%), followed by Shigella toxin-positive enterotoxigenic E. coli 220 
(41%) and Shigella/enteroinvasive E. coli (23%). The baseline characteristics of participants are 221 
listed in Table 1. Despite randomization, compared to the placebo group the CFZ group had by 222 
chance: more males (67% vs. 20%), lower body mass index (16.3±1.7 vs. 18.0±3.1 kg/m2), 223 
increased diarrhea output total stool weight (320.3±214.6 vs. 245.8±299.4 g), more pathogens 224 
detected at higher quantitiesa diarrheagenic amount per Global Enteric Multicenter Study 225 
(GEMS) criteria (67% vs. 30%) [14], more advanced HIV immunosuppression (CD4 counts 226 
25.3±24.4 vs. 170.4±321.7 cells/µL), and higher prevalence of C. parvum detected (58% vs. 227 
40%).  228 
 11 
 229 
Findings were similar for both ATP and ITT populations (Supplementary Table 1), and the ATP 230 
efficacy results are reported here. Stool Cryptosporidium excretion was persistent among Part A 231 
subjects throughout observation (Supplementary Figures 1 and 2), even at 41-55 days after the 232 
last dose. There was no significant difference in Cryptosporidium shedding in the CFZ group 233 
compared to placebo (Figures 2A-B). There was a trend towards increased change-from-baseline 234 
in Cryptosporidium shedding in the first stool of the day in the CFZ-treated group vs. placebo, 235 
with a difference in means of 2.17 log2 Cryptosporidium per gram ([95% upper confidence limit 236 
(CL): 3.82]), and in total Cryptosporidium shedding with a difference of means of 1.02 log2 237 
Cryptosporidium ([95% upper CL: 2.50]); the opposite result expected if CFZ was efficacious. 238 
There was no significant change in diarrhea in the CFZ group compared to placebo, whether 239 
measured by total stool weight change-from-baseline, number of diarrheal episodes, stool 240 
consistency grade, or severity diarrhea grade (Figures 2C-F).   241 
 242 
For the PK of CFZ in HIV-infected subjects without diarrhea or Cryptosporidium (Part B), 92 243 
were prescreened, 18 were screened, and 11 received CFZ, with one voluntary withdrawal during 244 
the inpatient phase. Part A subjects had about 2-fold less plasma exposure of CFZ than Part B 245 
subjects on day 5 (ratio AUC0-24: 0.607), and on day 1 of the inpatient dosing (ratio AUC0-24: 246 
0.478; Table 2, Figure 3; stool PK profiles are listed in Supplementary Appendix and 247 
Supplementary Figure 3).  248 
 249 
For safety, solicited AEs (Table 3) - expected in persons with diarrhea - were experienced by all 250 
subjects in both CFZ and placebo groups. There were higher numbers of solicited AEs 251 
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experienced in the CFZ group for diarrhea (9 (75%) vs. 4 (40%) in placebo), abdominal pain (8 252 
(67%) vs. 7 (70%) in placebo), and malaise (6 (50%) vs. 3 (30%) in placebo), and more severe 253 
solicited AEs in the CFZ group (2 (17%)) than the placebo group (0 (0%); Supplementary 254 
Figures 4 and 5).  No Part B subject experienced any solicited AE. The number of unsolicited 255 
AEs (Supplementary Table 2) was highest in the CFZ group (13 vs. 12 in placebo and 3 in Part 256 
B); the number of subjects who experienced AEs with fatal outcome was also higher in the CFZ 257 
group (3 (25%) vs. 1 (10%) in placebo and none in Part B; Supplementary Appendix). None of 258 
the fatalities were judged by the study medical monitors and DSMB to be CFZ-related 259 
(Supplementary Appendix).  260 
 261 
Discussion 262 
This is the first randomized, double-blind, placebo-controlled Phase 2a trial to evaluate CFZ for 263 
treatment of cryptosporidiosis in HIV-infected adults. The trial demonstrated that CFZ had no 264 
significant impact on Cryptosporidium shedding of the parasite, or on diarrheal episodes, stool 265 
weight, and consistency, compared to placebo. Evaluation of Cryptosporidium shedding in the 266 
first stool of the day provided similar data to total daily Cryptosporidium shedding. The drug is 267 
generally well-tolerated. Four patients died, three of whom received CFZ and the fourth placebo. 268 
This rate of death was consistent with our a priori estimates and each case was reviewed by the 269 
independent DSMB. CFZ achieved 2-fold less plasma exposure among Part A subjects with 270 
diarrhea vs. Part B subjects without diarrhea.  271 
 272 
The trial did show that HIV-infected adults with ≥3 days of diarrhea consistently excreted 273 
Cryptosporidium in their stools, even when assayed up to 60 days after enrollment.  This 274 
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demonstrates that this population would be appropriate to study the antiparasitic benefit of anti-275 
Cryptosporidium drugs that do not depend on the immune response. 276 
 277 
The trial did not show a reduction in Cryptosporidium excretion in this population treated with 278 
CFZ vs. placebo. This was the case whether one compared the Cryptosporidium excretion by 279 
qPCR as determined by the concentration in the first stool of the day, or by determining the total 280 
Cryptosporidium excreted per day. In fact, there was a non-significant trend towards slightly 281 
increased Cryptosporidium shedding in the CFZ group vs. the placebo, which was most evident 282 
at day 2 of study drug dosing. The trend towards increased shedding may reflect the more ill 283 
status of the CFZ subjects at baseline, as documented in their enrollment labs and health status. 284 
With a median HIV CD4 count of 23.5 cells/mm3 (IQR 11.75, 43.75) and viral load of 168,097.5 285 
copies/mL (IQR 94,044, 643,812.3), the mortality rate of 18% in the trial likely reflects 286 
advanced disease in our Part A cohort as a whole. 287 
 288 
Within our cohort, compared to placebo, the CFZ group had more deaths, SAEs, and severe 289 
solicited AEs. All subjects with cryptosporidiosis reported the solicited AEs expected with CFZ, 290 
such as diarrhea, abdominal pain, malaise and nausea. However, these solicited AEs were 291 
present at baseline in Part A subjects, as might be expected in this population with 292 
cryptosporidiosis, and solicited AEs were universal in both treatment groups. There tended to be 293 
less solicited AEs over time, which correlated with less severity in diarrhea during the hospital 294 
phase, and the severity of AEs tended to decrease over time. None of the Part B HIV-infected 295 
subjects without cryptosporidiosis exposed to the same dose of CFZ reported solicited AEs, and 296 
only 3 Part B subjects reported unsolicited AEs, and these were generally mild.  297 
 14 
 298 
A previous clinical trial for cryptosporidiosis treatment identified multiple safety concerns 299 
related to the health status of participants. This Phase 1-2 trial of miltefosine to treat HIV-related 300 
cryptosporidiosis in Zambian adults with chronic diarrhea was terminated early due to high 301 
mortality, lack of efficacy and development of SAEs that were attributed to the extreme 302 
metabolic abnormalities already present in patients enrolled in the trial [15]. In our trial, subjects 303 
with cryptosporidiosis also presented with electrolyte abnormalities, most commonly 304 
hypokalemia that required correction, and for some subjects required corrective treatment 305 
continued through the trial. In addition, there was also a very high incidence of active TB in the 306 
HIV-infected screening population. Screening by chest x-ray was inadequate likely because 307 
dehydrated subjects often do not have an infiltrate until rehydrated. Screening of sputum by 308 
GeneXpert or gram stain also was inadequate due to inability of dehydrated subjects to produce 309 
sputum. Urine LAM screening was instituted based on findings from other studies describing 310 
urine LAM as a predictor of disseminated TB and mortality in HIV-infected adults with low 311 
CD4 counts [16]. All deaths in our study were reported prior to instituting urine LAM screening 312 
at baseline. Once urine LAM screening was instituted [16], Notably, 43% of our otherwise 313 
eligible subjects subsequently tested positive by urine LAM and were excluded.  314 
 315 
Part A participants were extremely immunosuppressed. Most had CD4 counts <25 cells/µL and 316 
high HIV viral loads. Plasma levels of HIV medicines were detected at similar levels to Part B 317 
subjects (unpublished data), suggesting that these Part A subjects were compliant with first-line 318 
ARV therapy and that ARV resistance might be driving HIV treatment failure. Therefore, 319 
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screening for diarrhea in this population, and especially for Cryptosporidium, delineated those 320 
more at risk for TB and ARV failure.  321 
 322 
The predominant Cryptosporidium species was C. parvum subtype family IIc anthroponotic 323 
(10/11, 91% of those with C. parvum). This was unexpected, given that the majority of 324 
Cryptosporidium species identified in the pediatric Global Enteric Multicenter Study (GEMS) 325 
and adult studies were C. hominis [17-20]. However, a high prevalence of C. parvum has been 326 
noted in HIV/AIDS patients in Ethiopia, where 92/140 (66%) of HIV/AIDS patients were 327 
positive by PCR-RFLP [21]. As C. parvum has been observed to be associated with prolonged 328 
diarrhea in HIV-positive persons more frequently than C. hominis [17] the trial inclusion criteria 329 
may have selected for this species.  330 
 331 
Multiple copathogens were observed in stool, which may have contributed to the diarrhea [3], 332 
but Cryptosporidium may have driven the diarrhea in at least 15 of 22 subjects in this 333 
trial.patients with symptomatic diarrhea were routinely treated with ciprofloxacin as standard of 334 
care. In these 15 subjects, Cryptosporidium may have driven the diarrhea in at least 15 of 22 335 
subjects in this trial, as it Cryptosporidium was the pathogen with the lowest Ct value, and may 336 
have been the pathogen in the greatest quantity shed in stool. After applying GEMS cutoffs, 337 
which are based onuse Ct counts to determine clinically relevant diarrhea [14], only 7 338 
Cryptosporidium samples met diarrheagenic cutoffs, and only 11 samples met diarrheagenic 339 
pathogen criteria. Given thatAs GEMS data were based on children, the lack of correlation 340 
between Ct value and clinical diarrhea likely reflects the differences seen in an adult population 341 
with severe HIV immunosuppression with prolonged diarrhea.  342 
 16 
 343 
Our PK data suggests that diarrhea and/or Cryptosporidium infection negatively impacts CFZ 344 
plasma exposure. Since efficacy is likely driven by CFZ levels in the parasite, which may not be 345 
well-exposed to intraluminal CFZ as it is located in a vacuole under the epithelial plasma 346 
membrane, and faces in towards the gut lumen [22], plasma levels may not reflect efficacy as it 347 
would for systemic infections. The fact that serum CFZ levels in persons with well-suppressed 348 
HIV were twice as high suggests that in the setting of Cryptosporidium infection, the drug was 349 
not well absorbed. We propose that lower levels of CFZ likely exist in the epithelium layer in the 350 
Part A subjects, as passage through the gastrointestinal epithelium is required for access to the 351 
plasma. These lower levels may have contributed to the failure of efficacy against 352 
Cryptosporidium. However, we used the maximum dosage of CFZ that is accepted as safe in this 353 
trial [12], therefore increasing the dosage to improve efficacy may not be feasible. An 354 
intravenous form of clofazimine, described in the past [23], may have provided better systemic 355 
delivery of the drug; however, this was not a formulation available at the time of the trial.  356 
 357 
One of the limitations of the study was the small sample size. This led to slightly uneven 358 
randomization (12 vs. 10) based on block size. Also, imbalances in the baseline characteristics 359 
were noted in the Part A subjects CFZ vs. placebo groups, with the CFZ group being more ill at 360 
baseline. One possible confounder was the presence of multiple co-pathogens in the stool, which 361 
could have influenced diarrhea resolution.  362 
 363 
This trial provides important information for testing the efficacy of anti-Cryptosporidium 364 
therapeutics. There is a huge unmet need for Cryptosporidium drugs for young children and 365 
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immunocompromised individuals [9]. Despite a growing interest in moving promising pre-366 
clinical drugs into clinical trials there was, until this trial, few placebo-controlled trials in adults 367 
[24-26] and limited data on how to test the drugs in Phase 2a. This trial shows that HIV-infected 368 
adults with Cryptosporidium infection excrete Cryptosporidium consistently and thus the effects 369 
of treatment on Cryptosporidium excretion would be a feasible way to monitor for efficacy in 370 
Cryptosporidium therapy.  371 
 372 
For the conduct of future human experimental trials of cryptosporidiosis in this population, this 373 
study suggests that: 1) the screening population should be evaluated for TB detection, through 374 
urine LAM, and for electrolyte disturbances, particularly hypokalemia; 2) use of stool RDT in 375 
screening and ELISA tests on serial stools is not as sensitive as qPCR, and that we need only use 376 
qPCR to enroll and follow participants for Cryptosporidium excretion over time; 3) following 377 
serial Cryptosporidium shedding by qPCR of the first stool of the day, rather than total stool 378 
collection, is probably sufficient to assess efficacy; 4) given the ill status of enrolled subjects, an 379 
inpatient trial is merited and AEs and deaths may complicate safety evaluation of new study 380 
drugs; and 5) future trials would need to be multisite given the slow recruitment rate. There was, 381 
until this trial, few placebo-controlled trials in adults [24-26] and limited data on how to test the 382 
drugs in Phase 2a. This trial shows that HIV-infected adults with cryptosporidiosis excrete the 383 
parasite consistently and thus the effects of treatment on excretion would be a feasible way to 384 
monitor for efficacy in Cryptosporidium therapy.  385 
 386 
  387 
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In conclusion, CFZ was not effective in this trial at reducing Cryptosporidium excretion nor in 388 
resolving diarrhea in HIV-infected subjects with cryptosporidiosis. The decreased plasma 389 
exposure of CFZ in the Part A vs. Part B subjects may have influenced the efficacy of CFZ on 390 
Cryptosporidium; however, the highest recommended dose of CFZ was used for this trial, and 391 
further studies on safety and perhaps CFZ formulation would be necessary to increase the dose 392 
and exposure. Tthis is the first controlled clinical trial to assess the safety, efficacy, and PK of 393 
CFZ for treatment of cryptosporidiosis. , and aAlthough CFZ does not show promise as a novel 394 
therapeutic for Cryptosporidium infection, future human studies can use an approach based on 395 
lessons learned in this trial to assess the therapeutic potential of drugs for treatment of 396 
cryptosporidiosis.   397 
 398 
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Figure legends 421 
Figure 1. Part A trial profile 422 
ATP, according to protocol; ITT, intention to treat 423 
aSubject died after completing visit. 424 
bOne subject withdrew during inpatient phase but provided final blood draw. 425 
Figure 2. Treatment response in the according to protocol group:  426 
A) Mean change from baseline (CFB) in log number of cryptosporidium shed in first 427 
collected stool over time  428 
B) Mean CFB in total daily cryptosporidium shedding over time  429 
C) Mean CFB in total stool weight over time 430 
D) Mean number of diarrheal episodes over time  431 
E) Proportion of most severe stool consistency grade by time  432 
F) Proportion of most severe diarrhea grade by time  433 
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Figure 3. Mean plasma concentration of CFZ in plasma by time 434 
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Table 1. Baseline characteristics of participants  626 
Characteristic Part A CFZ group 
(n=12) 
Part A placebo 
group (n=10) 
Part B CFZ 
group (n=11) 
Age, years  39.8 (7.8) 39.1 (12.0) 44.1 (9.6) 
Male sex (%) 8 (67%) 2 (20%) 7 (64%) 
BMI, kg/m2  16.3 (1.7) 18.0 (3.1) 18.9 (1.4) 
Pulse rate, beats/min 90.9 (12.4) 95.9 (14.9) 78.1 (6.7) 
Systolic blood pressure, 
mmHg 
99.3 (15.0) 106.4 (16.5) 116.5 (11.8) 
Diastolic blood pressure, 
mmHg 
68,3 (10.1) 71.2 (8.8) 75.7 (12.3) 
Hemoglobin, g/dL 10.6 (2.2) 10.8 (2.8) 14.0 (1.3) 
 29 
Hematocrit, % 32.3 (6.5) 32.6 (8.7) 42.3 (3.6) 
White blood cells, 109/L 2.9 (1.4) 3.8 (2.8) 5.0 (1.7) 
Neutrophils, 109/L 1.6 (0.9) 2.1 (2.1) 2.5 (1.2) 
Lymphocytes, 109/L 0.8 (0.5) 1.1 (0.7) 2.0 (0.8) 
CD4 absolute, cells/µL    
Mean (SD) 25.3 (24.4) 170.4 (321.7) 422.0 (231.3) 
Median (IQR) 23.0 (8.0, 32.0) 22.5 (17.0, 86.0) 361.0  
(216.0, 634.0) 
HIV viral load, copies/µL  241,981.5 
(262,806.03) 
679,025.13 
(929,116.49) 
257.5 (805.7) 
ARV duration, days  1424 (1547.6) 2011 (1409.3) 1265 (1810.3) 
Blood urea nitrogen, 
mmol/L 
4.9 (2.5) 3.9 (1.1) 3.8 (1.0) 
Creatinine, µmol/L 82.0 (37.2) 56.0 (15.9) 65.4 (14.0) 
Alanine aminotransferase, 
IU/L 
34.0 (20.3) 40.3 (19.5) 38.9 (21.4) 
Aspartate aminotransferase, 
IU/L 
50.6 (16.4) 63.0 (30.4) 50.7 (18.3) 
Electrocardiogram (ECG)    
Normal (%) 11 (92%) 10 (100%) 11 (100%) 
Abnormal, not clinically 
significant (%) 
1 (8%) 0 (0%) 0 (0%) 
 30 
QTc interval, ms 421.7 (14.2) 418.3 (17.0) 409.7 (21.6) 
Cryptosporidium spp. (%)    
C. parvum 7 (58%) 4 (40%) N/A 
C. hominis 2 (17%) 1 (10%) N/A 
C. meleagridis 1 (8%) 3 (30%) N/A 
C. viatorum 1 (8%) 0 (0%) N/A 
Unknowna 1 (8%) 2 (20%) N/A 
Co-pathogens detected at 
diarrheagenic amount [14] 
(%) 
8 (67%) 3 (30%) N/A 
Diarrhea duration,b days 17 (7.6) 34 (57) N/A 
Stool ELISA positivity 
(D1, %) 
7 (58%) 2 (20%) N/A 
Log number of 
cryptosporidium shed in 
first collected stool of day, 
Cryptosporidium per gram 
stool (D-1) 
13.9 (2.7) 15.0 (2.2) N/A 
Total daily cryptosporidium 
shedding, Cryptosporidium 
per gram stool (D-1) 
22.3 (2.9) 22.1 (3.2) N/A 
Total stool weight, g (D-1) 320.3 (214.6) 245.8 (299.4) N/A 
Formatted: Superscript
 31 
Most severe diarrhea 
severity gradeb gradec 
(mild)  
9 (75%) 3 (30%) N/A 
Stool consistency severity 
grade ≥3 (D-1, %) 
9 (75%) 6 (67%) N/A 
Number of diarrheal 
episodes,b c D1 
1.3 (1.1) 0.8 (1.3) N/A 
ARV, antiretroviral therapy; BMI, body mass index; D, day; IQR, interquartile range; SD, 627 
standard deviation 628 
All values are mean (SD) unless otherwise listed. 629 
aFailed to amplify on sequencing of 18s and gp60. 630 
bSubjects with diarrhea duration entries ‘>2 weeks’ were treated as 21 days for calculations of 631 
summary statistics. 632 
cObserved over the first 24-hour dosing interval after the first study dose.  633 
 634 
 635 
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 639 
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 641 
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 645 
 646 
 647 
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 653 
Table 2. Comparison of pharmacokinetic parameters in Part A and B subjects 654 
PK parameter Part A (n=12) Part B (n=11) 
Mean (SD) % CV Mean (SD) % CV 
Day 1 Cmin (ng/mL) 35.83 (37.28) 323 74.74 (24.51) 46 
 Cmax (ng/mL) 97.55 (117.9) 195 193.3 (93.50) 58 
 Tmax (h) 19.73 (5.67) - 14.776 (7.537) - 
 AUC0-24 (ng.h/mL) 1364.0 (1754.0) 219 2851.0 (1256.0) 50 
Day 5 Cmin (ng/mL) 258.8 (353.1) 187 455.8 (221.5) 47 
 Cmax (ng/mL) 280.7 (355.2) 173 514.1 (202.0) 39 
 Tmax (h) 9.679 (10.81) - 6.683 (3.765) - 
 AUC0-24 (ng.h/mL) 6863.0 (8552.0) 172 11298.0 (5580.0) 59 
 33 
Summary t1/2 (h)
a 336.5 (84.71) 25 535.5 (4.950) 1 
 RAUC 5.905 (3.516) 57 4.111 (1.579) 50 
AUC, area under the curve; Cmax, peak plasma concentration; Cmin, trough plasma 655 
concentration; CV, coefficient of variation; RAUC, accumulation ratio for AUC0-24 for Day 5 to 656 
Day 1; SD, standard deviation; Tmax, time to reach Cmax; t1/2, elimination half-life 657 
aElimination half-life of clofazimine was previously found to be up to 70 days upon repeat dose 658 
administration;[26] [27]; therefore the relatively short plasma sampling schedule in this study 659 
may not be accurately capture the t1/2 parameter in these populations. 660 
 661 
 662 
 663 
 664 
Table 3. Summary of adverse events 665 
  Part A – CFZ 
(n=12) 
Part A – 
placebo (n=10) 
Part B (n=11) 
Any solicited 
adverse event  
Any severity 12 (100%) 10 (100%) 0 (0%) 
Max severity 2 (17%) 0 (0%) 0 (0%) 
Abdominal pain  Any severity 8 (67%) 7 (70%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Vomiting  Any severity 4 (33%) 4 (40%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Diarrhea  Any severity 9 (75%) 4 (40%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
 34 
Anorexia  Any severity 4 (33%) 3 (30%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
Skin 
discoloration 
Any severity 0 (0%) 0 (0%) 0 (0%) 
Nausea Any severity 5 (42%) 5 (50%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0 (0%) 
Malaise Any severity 6 (50%) 3 (30%) 0 (0%) 
Max severity 1 (8%) 0 (0%) 0(0%) 
Urgency of 
defecation 
Any severity 5 (42%) 4 (40%) 0 (0%) 
Max severity 0 (0%) 0 (0%) 0 (0%) 
Any adverse events with fatal 
outcome 
3 (25%) 1 (10%) 0 (0%) 
Number of unsolicited adverse 
events 
13 12 3 
Subjects with at least one 
unsolicited adverse event 
6 (50%) 4 (40%) 3 (27%) 
Subjects with a serious adverse 
event  
5 (42%) 2 (20%) 0 (0%) 
Any unsolicited adverse event 
related to study drug 
2 (17%) 0 (0%) 3 (27%) 
Any unsolicited adverse event 
leading to discontinuation of study 
drug  
0 (0%) 1 (10%) 0 (0%) 
 35 
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